<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312465782</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312465782</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Alijotas-Reig</surname><given-names>J</given-names></name>
<xref ref-type="corresp" rid="corresp1-0961203312465782"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203312465782">Systemic Autoimmune Diseases Unit, Department of Internal Medicine-1, Vall d’Hebron University Hospital, Barcelona, Spain</aff>
<aff id="aff2-0961203312465782">Department of Medicine, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain</aff>
<author-notes>
<corresp id="corresp1-0961203312465782">Correspondence to: Jaume Alijotas-Reig, Systemic Autoimmune Diseases Unit, Department of Internal Medicine-1, Vall d’Hebron University Hospital, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain. Email: <email>16297jar@comb.es</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>1</issue>
<fpage>6</fpage>
<lpage>17</lpage>
<history>
<date date-type="received"><day>10</day><month>9</month><year>2012</year></date>
<date date-type="accepted"><day>2</day><month>10</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec01-0961203312465782"><title>Objective</title>
<p>To date, there are no reliable data regarding the actual treatment received by women with refractory obstetric antiphospholipid syndrome (OAPS). The aim of this study was to assess current clinical evidence and new trends in the treatment of refractory OAPS.</p>
</sec>
<sec id="sec02-0961203312465782" sec-type="methods"><title>Methods</title>
<p>A non-systematic but comprehensive literature search using relevant keywords was made to identify relevant articles published in English from different computerized databases: PubMed (Medline), Google Scholar electronic database search and The Cochrane Library, from January 2000 to March 2012. Studies on the treatment of poor obstetric outcomes in women with OAPS were included. Prospective randomized clinical trials, cohort studies, reviews, systematic reviews and meta-analysis were retrieved.</p>
</sec>
<sec id="sec03-0961203312465782" sec-type="results"><title>Results</title>
<p>A total of 130 articles were finally selected for this review, including 17 randomized clinical trials and four meta-analyses. The majority of articles were non-randomized original papers and basic and clinical reviews.</p>
</sec>
<sec id="sec04-0961203312465782" sec-type="conclusions"><title>Conclusion</title>
<p>Up to 20% of women with OAPS do not receive the currently recommended therapeutic regimen. Unfortunately, well-designed studies regarding the usefulness of new drugs in refractory OAPS are scarce. Hydroxychloroquine and low-dose prednisolone appear to be useful when added to standard therapy. Current data do not support the use of intravenous immunoglobulins in this field. The role played by double anti-aggregant therapy, fondaparinux, vitamin D, pentoxifylline and TNF-targeted therapies should be tested in well-designed studies.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Antiphospholipid antibody</kwd>
<kwd>complement activation</kwd>
<kwd>obstetric antiphospholipid syndrome</kwd>
<kwd>obstetric morbidity</kwd>
<kwd>refractory</kwd>
<kwd>treatment</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312465782" sec-type="intro"><title>Introduction</title>
<p>Antiphospholipid antibodies (aPL) are a family of autoantibodies that bind to negatively charged phospholipids, protein-binding phospholipids or both.<sup><xref ref-type="bibr" rid="bibr1-0961203312465782">1</xref></sup> The antiphospholipid syndrome (APS) is characterized by an increased risk of vascular thrombosis and/or pregnancy complications, both related to aPL, according to the Sydney recommendations.<sup><xref ref-type="bibr" rid="bibr2-0961203312465782">2</xref></sup> APS-related pregnancy morbidity encompasses recurrent miscarriages in the first trimester, fetal loss in the second and third trimesters, severe, early-onset pre-eclampsia and prematurity.<sup><xref ref-type="bibr" rid="bibr2-0961203312465782">2</xref></sup> aPL include lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-β2-glycoprotein-1 antibodies (anti-β2-GPI).<sup><xref ref-type="bibr" rid="bibr1-0961203312465782">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203312465782">2</xref></sup> Other aPL-related obstetric complications are: implantation failure (mainly following in vitro fertilization procedures), placental haematomas and abruptio placenta. Clinically, I believe consensus exists regarding different subsets of APS: in some patients, the aPL-related injury is only present as venous thromboembolic phenomena; in others as an arterial occlusion alone; in a third subgroup, only and often recurrently, as poor obstetrical outcomes; and, finally, a fourth subset of patients who may have a combination of the above-mentioned clinical events.<sup><xref ref-type="bibr" rid="bibr3-0961203312465782">3</xref></sup> When inflammation and/or thrombosis owing to aPL occur in the placenta without previous systemic thrombosis and where this is associated with the above-mentioned obstetrical complications, the syndrome is known as obstetric antiphospholipid syndrome (OAPS).<sup><xref ref-type="bibr" rid="bibr4-0961203312465782">4</xref>,<xref ref-type="bibr" rid="bibr5-0961203312465782">5</xref></sup> The currently accepted first-line treatment for OAPS is low-dose aspirin (LDA) plus prophylactic unfractionated or low-molecular-weight heparin (LMWH).<sup><xref ref-type="bibr" rid="bibr6-0961203312465782">6</xref>–<xref ref-type="bibr" rid="bibr11-0961203312465782">11</xref></sup> However, in approximately 20% of OAPS cases, the final endpoint, i.e. a live birth, cannot be achieved.<sup><xref ref-type="bibr" rid="bibr12-0961203312465782">12</xref>,<xref ref-type="bibr" rid="bibr13-0961203312465782">13</xref></sup> This is a challenging situation that requires careful management by the physician since no absolute data regarding this clinical situation exist. Herein, some therapeutic possibilities for this clinical scenario will be discussed.</p>
</sec>
<sec id="sec2-0961203312465782" sec-type="methods"><title>Methods</title>
<sec id="sec3-0961203312465782"><title>Search strategy</title>
<p>I performed a comprehensive, non-systematic literature search using the relevant keywords ‘recurrent miscarriage’, ‘recurrent pregnancy loss’, ‘antiphospholipid antibodies’, ‘antiphospholipid syndrome’ and ‘treatment’, to identify relevant articles published in English from two computerized databases: PubMed (Medline) and The Cochrane Library (2000–March 2012). Some interesting papers before 2000 were also reviewed and are included in this article.</p>
</sec>
<sec id="sec4-0961203312465782"><title>Criteria for selecting articles for this review</title>
<p>I selected studies devoted to the treatment of poor obstetric outcomes, mainly recurrent miscarriages, fetal losses and stillbirths related to aPL, particularly focusing on papers that included women suffering from full-blown APS. Several major articles about the pathogenesis of OAPS were also included in order to make the new therapeutic approaches more understandable. The articles included were: prospective randomized clinical trials, matched or non-matched case-control or cohort studies, reviews and systematic reviews. Study selection was based on existing clinical evidence. Unfortunately, well-designed studies of new drugs in treating refractory OAPS are scarce.</p>
</sec>
<sec id="sec5-0961203312465782"><title>Search results</title>
<p>A total of 130 articles were finally selected for this review, 57 of which were clinical studies in the therapeutic field: 4 meta-analyses, 30 revisions, 17 randomized clinical trials and 6 other original papers. The rest of the manuscripts included dealt with general aspects, pathophysiology and laboratory studies of OAPS. This review consists of a comprehensive analysis of the data obtained from these articles.</p>
</sec>
</sec>
<sec id="sec6-0961203312465782"><title>Epidemiology</title>
<p>The prevalence of APS in the general population is unknown, but has been estimated to be 0.5%.<sup><xref ref-type="bibr" rid="bibr14-0961203312465782">14</xref></sup> aPL can be detected in 1–5% of healthy women of childbearing age.<sup><xref ref-type="bibr" rid="bibr15-0961203312465782">15</xref></sup> Around 40% of women with systemic lupus erythematosus (SLE) have aPL; it is estimated that less than 40% of these will eventually develop thrombotic events.<sup><xref ref-type="bibr" rid="bibr16-0961203312465782">16</xref></sup></p>
<p>Between 10% and 25% of unexplained recurrent miscarriage are due to aPL. The prevalence of aPL in women with pregnancy loss varies widely, ranging from 5 to 50% (average 15.5%). The prevalence of LA oscillates between 0 and 14% (average 8%). In women suffering from fetal loss after week 20, the prevalence reaches 30%.<sup><xref ref-type="bibr" rid="bibr17-0961203312465782">17</xref></sup> Differences in these findings can be explained by the diversity of study groups, different inclusion criteria and lack of standardization in some aPL detection methods.<sup><xref ref-type="bibr" rid="bibr18-0961203312465782">18</xref></sup></p>
<p>Cervera et al.<sup><xref ref-type="bibr" rid="bibr19-0961203312465782">19</xref></sup> in a large cohort of 590 pregnant women from the Euro-Phospholipid Project, which included 1000 patients with APS, showed the prevalence of pre-eclampsia, eclampsia and abruption placenta to be 9.5%, 4.4% and 2.%, respectively. Similarly, in that study which included 1580 pregnancies, prevalence of early and late fetal loss was found to be 35.4% and 16.9%, respectively, while that of live births was 48%.</p>
<p>Alijotas-Reig et al.<sup><xref ref-type="bibr" rid="bibr12-0961203312465782">12</xref></sup> reported the preliminary data from the European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS) which included 211 women with 530 pregnancies.</p>
<p>In that study, the prevalence of early fetal loss and late fetal loss was 43.3% and 32.4%, respectively, while the prevalence of live births was almost 80% in the treated women and 20% in non-treated group.</p>
<p>Data on the prevalence of aPL in preeclampsia (PE) and PE-related subsets are scarce. In a recent study by our group, the prevalence of aPL in women with pre-eclampsia was 14% and 28% in HELLP syndrome (haemolysis, raised liver enzyme and thrombocytopenia).<sup><xref ref-type="bibr" rid="bibr20-0961203312465782">20</xref></sup> A relation between HELLP and APS is relatively common, probably due to shared pathogenic mechanisms. Catastrophic APS (CAPS) is a life-threatening form of APS, which appears with or complicates APS in 1% of cases. However, 5–6% of CAPS cases occur during pregnancy or puerperium.<sup><xref ref-type="bibr" rid="bibr21-0961203312465782">21</xref></sup></p>
</sec>
<sec id="sec7-0961203312465782"><title>Pathophysiology of OAPS</title>
<p>Classically, it has been accepted that aPL promote the activation of endothelial cells, monocytes and platelets, with subsequent up-regulation of intracellular cell adhesion molecule-1 and tissue factor (TF) with further clot pathway activation.<sup><xref ref-type="bibr" rid="bibr22-0961203312465782">22</xref>–<xref ref-type="bibr" rid="bibr24-0961203312465782">24</xref></sup> It now seems possible that different aetiologic mechanisms can explain different aPL-related complications (<xref ref-type="table" rid="table1-0961203312465782">Table 1</xref>). Thus, thrombotic and non-thrombotic underlying mechanisms may play a role in the pathogenesis of aPL-related injury, while non-thromboembolic pulmonary syndromes and obstetric complications related to aPL may be good examples of possible non-primary thrombotic, mainly inflammatory manifestations related to aPL or APS.<sup><xref ref-type="bibr" rid="bibr25-0961203312465782">25</xref>–<xref ref-type="bibr" rid="bibr27-0961203312465782">27</xref></sup> In these cases, inflammatory, complement-mediated, primary pathway activation appears to play a major role. A clot pathway may also be secondarily activated. Out et al.,<sup><xref ref-type="bibr" rid="bibr28-0961203312465782">28</xref></sup> Girardi et al.<sup><xref ref-type="bibr" rid="bibr29-0961203312465782">29</xref>,<xref ref-type="bibr" rid="bibr30-0961203312465782">30</xref></sup> and Holers et al.<sup><xref ref-type="bibr" rid="bibr31-0961203312465782">31</xref></sup> showed that many placentas from APS women who had had miscarriages were devoid of thrombosis. They demonstrated that the complement pathway may play an integral, major, role in the pathogenesis of pregnancy loss, totally unrelated to thrombotic or hormonal (gonadotropin)-blocking effects of aPL. Activation of the C3<sup><xref ref-type="bibr" rid="bibr29-0961203312465782">29</xref></sup> and C5<sup><xref ref-type="bibr" rid="bibr30-0961203312465782">30</xref></sup> complement proteins is also required for fetal loss to occur. These authors suggested that local complement activation could be a mechanism for damage not only of trophoblasts but also of vascular endothelium. Thus, in some cases, it is often not possible to provide evidence of decidual or placental thrombosis<sup><xref ref-type="bibr" rid="bibr32-0961203312465782">32</xref>,<xref ref-type="bibr" rid="bibr33-0961203312465782">33</xref></sup> but only inflammatory histopathologic signs, probably due to complement activation,<sup><xref ref-type="bibr" rid="bibr34-0961203312465782">34</xref></sup> TF over-expression<sup><xref ref-type="bibr" rid="bibr32-0961203312465782">32</xref></sup> and/or a negative imbalance of angiogenic factors.<sup><xref ref-type="bibr" rid="bibr35-0961203312465782">35</xref></sup> Furthermore, the increase in endometrial natural killer (NK) cells has been shown in some studies to be predictive of recurrent miscarriage, compared to normal fertile controls.<sup><xref ref-type="bibr" rid="bibr36-0961203312465782">36</xref>–<xref ref-type="bibr" rid="bibr38-0961203312465782">38</xref></sup> Cases of recurrent miscarriage have a higher percentage of CD16 + CD56dim NK cells and a lower percentage of CD16–CD56bright NK cells during the secretory phase of the endometrium.
<table-wrap id="table1-0961203312465782" position="float"><label>Table 1</label><caption><p>Pathogenic mechanisms related to antiphospholipid antibodies</p></caption>
<graphic alternate-form-of="table1-0961203312465782" xlink:href="10.1177_0961203312465782-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Thrombotic</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Inhibition of protein C activity (acquired protein C resistance)</td>
</tr>
<tr>
<td>Inhibition of protein S cofactor activity / inhibition of antithrombin III activity</td>
</tr>
<tr>
<td>TF up regulation in monocytes and endothelial cells</td>
</tr>
<tr>
<td>Inhibition of TF inhibitor / inhibition of t-PA activity</td>
</tr>
<tr>
<td>Lowering of endothelial cell prostacyclin synthesis</td>
</tr>
<tr>
<td>Increase of von Willebrant synthesis</td>
</tr>
<tr>
<td>Induction of platelet activation and aggregation</td>
</tr>
<tr>
<td>Interference of a protecting annexin A5 shield (annexin A5 resistance)</td>
</tr>
<tr>
<td>Inhibition of β<sub>2</sub>-glycoprotein I activity</td>
</tr>
<tr>
<td>Decrease of thrombomodulin levels</td>
</tr>
<tr>
<td>Increased microparticle formation and delivery</td>
</tr>
<tr>
<td>Proinflammatory cytokine synthesis</td>
</tr>
<tr>
<td><bold><italic>Non-thrombotic lesional mechanisms (trophoblast injury)</italic></bold></td>
</tr>
<tr>
<td>Impairment of trophoblast invasiveness</td>
</tr>
<tr>
<td>Increase of trophoblast apoptosis and reduced levels of β-hCG</td>
</tr>
<tr>
<td>Increase of TNFα, IL-6 and IL-1b; decrease of IL-3 levels</td>
</tr>
<tr>
<td>In situ classical and alternative complement activation</td>
</tr>
<tr>
<td>Increase of the Fc and C4-dependent protein</td>
</tr>
<tr>
<td>In situ generation of anaphylotoxins, mainly C3a / C5a-induced neutrophil / monocyte activation as well as TF over expression.</td>
</tr>
<tr>
<td>Peripheral low levels of C4 and C3 complement proteins</td>
</tr>
<tr>
<td>Higher concentration of inflammatory cells, particularly macrophages, neutrophils and probably decidual NK cells.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312465782"><p>t-PA: tissue-Plasminogen Activator; β-hCG: human chorionic gonadotropin; TF: tissue factor; NK: natural killer.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>CD16–CD56bright NK cells seem to play a key role in the preservation of pregnancy.<sup><xref ref-type="bibr" rid="bibr39-0961203312465782">39</xref></sup> Similarly, decidual NK3 increase and peripheral NK1 are usually detected in normal pregnancies, in contrast to cases of recurrent miscarriage. The question is why NK cells become activated and later attack the trophoblast.<sup><xref ref-type="bibr" rid="bibr40-0961203312465782">40</xref></sup> Human chorionic gonadotropin (hCG) is related to IL-6, a prothrombotic cytokine,<sup><xref ref-type="bibr" rid="bibr41-0961203312465782">41</xref></sup> and progesterone inhibits the number and activity of NK cells.<sup><xref ref-type="bibr" rid="bibr42-0961203312465782">42</xref>,<xref ref-type="bibr" rid="bibr43-0961203312465782">43</xref></sup> Thus, in these cases, a lack of progesterone may lead to activation of NK cells, thereby contributing to eventual miscarriage. Therefore, NK cell activation may be only part of the mechanism of miscarriage or it may be its cause. Recently, Carp and Shoenfeld<sup><xref ref-type="bibr" rid="bibr44-0961203312465782">44</xref></sup> and Perricone et al.<sup><xref ref-type="bibr" rid="bibr45-0961203312465782">45</xref></sup> reported that patients with APS and recurrent miscarriage have higher levels of NK cells than those with APS but no miscarriage. In the same way, activated NK cells provoke an increase in trophoblast cell apoptosis, which reduces hCG production, thereby closing the circle.<sup><xref ref-type="bibr" rid="bibr44-0961203312465782">44</xref></sup> Furthermore, Berman et al.<sup><xref ref-type="bibr" rid="bibr46-0961203312465782">46</xref></sup> have shown TNF-alpha to be a critical effector in aPL-related placental injury and further miscarriage. A direct effect of aPL on trophoblast cells has been demonstrated through in vitro and animal studies.<sup><xref ref-type="bibr" rid="bibr47-0961203312465782">47</xref>,<xref ref-type="bibr" rid="bibr48-0961203312465782">48</xref></sup> Recent studies conducted by Di Simone et al.<sup><xref ref-type="bibr" rid="bibr49-0961203312465782">49</xref></sup> and D’Ippolito et al.<sup><xref ref-type="bibr" rid="bibr50-0961203312465782">50</xref></sup> demonstrated the ability of aPL to affect the maternal side of the placenta by directly binding human endometrial endothelial cells (HEECs). Accordingly, aPL induced a significant decrease in both the number and total length of capillaries formed by HEECs in an in vitro assay and in vivo murine model.<sup><xref ref-type="bibr" rid="bibr50-0961203312465782">50</xref></sup> Altogether, these observations indicate that aPL acts in the placental bed via multiple pathogenic mechanisms, finally reducing trophoblast invasion, causing impairment in HEEC differentiation, interfering with physiological placentation and explaining the APS-linked complications of pregnancy.</p>
</sec>
<sec id="sec8-0961203312465782"><title>Treatment of OAPS</title>
<p>Currently, the management of APS centres on abrogating the procoagulant state whilst balancing the potential risks of anticoagulant therapy.<sup><xref ref-type="bibr" rid="bibr14-0961203312465782">14</xref>,<xref ref-type="bibr" rid="bibr16-0961203312465782">16</xref>,<xref ref-type="bibr" rid="bibr51-0961203312465782">51</xref></sup> It is important to emphasize that women with aPL, particularly those with SLE or a high-risk antibody profile, are probable candidates for long-term primary thromboprophylaxis with LDA.<sup><xref ref-type="bibr" rid="bibr52-0961203312465782">52</xref></sup> OAPS should be treated by a multidisciplinary team of specialists including rheumatologists, gynaecologists, haematologists and internists with experience in this field. In OAPS, secondary thromboprophylaxis with LDA and heparin, either non-fractionated or LMWH in diverse doses is the mainstay of treatment, according to the results of nine randomized clinical trials<sup><xref ref-type="bibr" rid="bibr14-0961203312465782">14</xref>,<xref ref-type="bibr" rid="bibr53-0961203312465782">53</xref>,<xref ref-type="bibr" rid="bibr54-0961203312465782">54</xref></sup> (<xref ref-type="table" rid="table2-0961203312465782">Table 2</xref>). Usually, hydroxychloroquine is added for patients suffering from SLE.<sup><xref ref-type="bibr" rid="bibr55-0961203312465782">55</xref>,<xref ref-type="bibr" rid="bibr56-0961203312465782">56</xref></sup> Cases with previous thrombotic events require secondary thromboprophylaxis with full unfractionated or LMWH doses or anti-vitamin K therapy (except for weeks 5 to 12 of gestation), mainly warfarin or acenocumarol. However, recurrent thromboses and poor obstetric outcomes have been reported to occur despite optimum recommended therapy.<sup><xref ref-type="bibr" rid="bibr12-0961203312465782">12</xref>,<xref ref-type="bibr" rid="bibr21-0961203312465782">21</xref></sup> Alternative therapies have been suggested, mainly in thrombotic forms, but are still subject to debate. Several options have been used in women in whom standard treatment fails and embryo/fetal morbidities recur. Henceforth, I will focus on possible management strategies for refractory OAPS.
<table-wrap id="table2-0961203312465782" position="float"><label>Table 2</label><caption><p>Suggested regimens for the treatment of antiphospholipid syndrome in pregnancy</p></caption>
<graphic alternate-form-of="table2-0961203312465782" xlink:href="10.1177_0961203312465782-table2.tif"/>
<table frame="hsides">
<tbody align="left">
<tr>
<td>A/ Women with antiphospholipid syndrome without previous thrombosis and recurrent early (pre-embryonic or embryonic) miscarriage: Low dose aspirin together with either prophylactic unfractionated heparin (5000–7500 IU subcutaneously every 12 h) or LMWH (enoxaparin, tinzaparin, bemiparin or dalteparin, in usual prophylactic doses SC/24 h) (Grade 1B). Following delivery, postpartum thromboprophylaxis with warfarin or better, LMWH is indicated for 6 weeks§.</td>
</tr>
<tr>
<td>B/ Women with antiphospholipid syndrome without previous thrombosis and isolated or recurrent foetal death (more than 10 weeks' gestation) or previous early delivery (&lt; 34 weeks gestation) due to early severe pre-eclampsia or placental insufficiency: Low-dose aspirin plus prophylactic or intermediate-unfractionated heparin (7500–10 000 IU subcutaneously every 12 h, or every 8–12 h adjusted to maintain the mid-interval a PTT* 1.5 times the control mean) or LMWH (usual low or intermediate-prophylactic doses i.e: Enoxaparin 40 mg or 60 mg SC/ 24 h). Following delivery, postpartum thromboprophylaxis with warfarin or better, LMWH is indicated for 6 weeks§.</td>
</tr>
<tr>
<td>C/ Women with antiphospholipid syndrome and previous thrombosis: Low-dose aspirin plus therapeutic unfractionated heparin (subcutaneously every 8–12 h adjusted to maintain the mid-interval aPTT* or heparin concentration (anti-FXa activity* in the therapeutic range) or LMWH (therapeutic dose-i.e: enoxaparin 1 mg/kg subcutaneously, or dalteparin 100 U/kg subcutaneously every 12 h, or enoxaparin 1.5 mg/kg/day subcutaneously, or dalteparin 200 U/kg/day subcutaneously)†. Following delivery, thromboprophylaxis (secondary) with warfarin or LMWH (therapeutic dose) is indicated long life§.<hr/></td>
</tr>
<tr>
<td>aPTT: activated partial thromboplastin time. LMWH: low-molecular-weight heparin.*: Women without a lupus anticoagulant in whom the aPTT is normal can be monitored with the aPTT. Women with lupus anticoagulant should be monitored with anti-factor Xa activity. †: Need for dose adjustments over the course of pregnancy remains controversial. Some experts argue that in the absence of better evidence, it is prudent to monitor anti-factor Xa LMWH concentrations 4–6 h after injection with dose adjustment to maintain a therapeutic anti-factor Xa concentration (0.6 to 1.1 U/mL) if a twice-daily regimen is used. Slightly higher if a once-daily regimen is chosen). §: Lactation is not a contra-indication for warfarin or heparins use.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203312465782"><p>Modified from American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)<sup>53</sup> and Bates et al.<sup>54</sup></p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec9-0961203312465782"><title>Management of refractory OAPS</title>
<p>APS is often a treatable cause of pregnancy loss; however, in up to 20–30% of cases, poor obstetric outcomes, particularly recurrent miscarriage, persist despite treatment.<sup><xref ref-type="bibr" rid="bibr23-0961203312465782">23</xref>,<xref ref-type="bibr" rid="bibr25-0961203312465782">25</xref></sup> According to preliminary data from the European Registry on Obstetric Antiphospholipid Syndrome,<sup><xref ref-type="bibr" rid="bibr12-0961203312465782">12</xref></sup> the recommended therapeutic schedule, i.e. LDA plus prophylactic heparin, was only given in 87.1% of women suffering from full-blown OAPS. Overall, live births were obtained in 79.4% of cases, with 20.6% failures. These data concur with the majority of published articles in this field. From now on, the term refractory OAPS will be used to describe cases in which poor obstetric outcomes persist even when a standard therapeutic regimen is used to treat OAPS. Accordingly, the first approach is to treat women with OAPS appropriately, using the standard accepted therapeutic regimens (<xref ref-type="table" rid="table2-0961203312465782">Table 2</xref>).</p>
<p>According to new aetiopathogenic pathways for OAPS, and to new mechanisms of action for commonly used drugs, i.e. LMWH, as well as the therapeutic properties of other drugs used alone or in combination, new therapeutic proposals may be considered in these challenging clinical situations.</p>
<sec id="sec10-0961203312465782"><title>Anticoagulants: heparins and related compounds</title>
<p>Heparin exerts other pharmacological effects beyond its antithrombotic properties. In fact, a large body of evidence shows that heparin has anti-inflammatory and immune-modulating properties. In the fetal–placental interface, heparin plays a role in trophoblast cells by increasing cellular invasion and enhancing the activity of specific proteases. In in vitro studies, Hills et al.<sup><xref ref-type="bibr" rid="bibr57-0961203312465782">57</xref></sup> demonstrated that heparin abrogates villous trophoblast cell apoptosis in response to proinflammatory cytokines. In a recent article, Di Simone et al.<sup><xref ref-type="bibr" rid="bibr48-0961203312465782">48</xref></sup> showed that LMWH promotes the survival of human decidual cells undergoing apoptosis in response to TNF-alpha. Heparins are able to bind anionic molecules such as aPL, and block complement pathway activation.<sup><xref ref-type="bibr" rid="bibr58-0961203312465782">58</xref>–<xref ref-type="bibr" rid="bibr60-0961203312465782">60</xref></sup> Other anti-inflammatory effects of LMWH have been postulated to be specifically TNF-alpha-mediated.<sup><xref ref-type="bibr" rid="bibr61-0961203312465782">61</xref></sup> However, new interesting considerations regarding heparin usage are worthy of mention. The timing of heparin administration can be a determinant of success. Thus, in cases of refractory OAPS, we could start heparin treatment in the early stages of gestation, without waiting for ultrasound examination. Similarly, Di Simone et al.<sup><xref ref-type="bibr" rid="bibr48-0961203312465782">48</xref></sup> demonstrated that not all LMWHs abrogate the trophoblast injury related to aPL with the same intensity. LMWH preparations differ in their molecular weight, half-life, anti-Factor IIa /anti-Factor Xa activity, their ability to prevent trophoblast-mediated apoptosis and in their complement-binding capacity. Thus, in vitro, tinzaparin seems to be better than enoxaparin in blocking these latter injury mechanisms. Finally, another related compound, fondaparinux, which is not really a LMWH, and which had previously been reported as non-effective in animal models of OAPS,<sup><xref ref-type="bibr" rid="bibr62-0961203312465782">62</xref></sup> may play a role in the new therapeutic regimens for refractory OAPS. Fondaparinux is a synthetic pentasaccharide whose antithrombotic activity is the result of anti-thrombin-mediated selective inhibition of Factor Xa (FXa). Neutralization of FXa interrupts the blood coagulation cascade and thus inhibits thrombin formation and further thrombus development.<sup><xref ref-type="bibr" rid="bibr63-0961203312465782">63</xref></sup> In animal models, fondaparinux is able to prevent endothelial damage, and to bind anionic molecules such as β2GP-I as well as β2GP-I/anti-β2GP-I complexes.<sup><xref ref-type="bibr" rid="bibr64-0961203312465782">64</xref></sup> Furthermore, Amara et al.<sup><xref ref-type="bibr" rid="bibr65-0961203312465782">65</xref></sup> have reported the ability of fondaparinux to block FXa–C3 cleavage, and probably further delivery of C3a and C5a. Fondaparinux, compared with certain LMWHs, may also improve angiogenic processes.<sup><xref ref-type="bibr" rid="bibr66-0961203312465782">66</xref></sup> Finally, in an in vitro study, IL-10 given together with fondaparinux potentiated the inhibitory effect of fondaparinux on thrombin generation via TF expression.<sup><xref ref-type="bibr" rid="bibr67-0961203312465782">67</xref></sup> Considering these new mechanisms of action, fondaparinux could be worth considering for use in refractory OAPS.</p>
</sec>
<sec id="sec11-0961203312465782"><title>Antimalarials</title>
<p>Observational and in vitro studies have demonstrated the antithrombotic effect of antimalarials, mainly in patients with APS and particularly when associated with SLE.<sup><xref ref-type="bibr" rid="bibr55-0961203312465782">55</xref>,<xref ref-type="bibr" rid="bibr56-0961203312465782">56</xref>,<xref ref-type="bibr" rid="bibr68-0961203312465782">68</xref>,<xref ref-type="bibr" rid="bibr69-0961203312465782">69</xref></sup> Antimalarials have many anti-inflammatory, anti-aggregant and immune-regulatory properties: they inhibit phospholipase activity, stabilize lysosomal membranes, block the production of several pro-inflammatory cytokines and, in addition, impair complement-dependent antigen–antibody reactions.<sup><xref ref-type="bibr" rid="bibr70-0961203312465782">70</xref>,<xref ref-type="bibr" rid="bibr71-0961203312465782">71</xref></sup> In recent years, Rand and colleagues<sup><xref ref-type="bibr" rid="bibr72-0961203312465782">72</xref>–<xref ref-type="bibr" rid="bibr76-0961203312465782">76</xref></sup> have published articles on the anticoagulant properties of the annexin A5 (AnxA5) molecule and its relationship with prothrombotic status as induced by aPL. AnxA5 is a potent anticoagulant protein, with a high affinity for anionic phospholipids, and forms part of a lattice structure over phospholipid bilayers, thereby shielding and preventing phospholipid-dependent coagulation pathway activation. AnxA5 expression is high on the apical membranes of placental villous syncytiotrophoblasts, endothelial cells and platelets. When aPL are present, they impede AnxA5 binding by competitive displacement by aPL–IgG–β2GP I complexes. The reduction in AnxA5 over the cell surface leads to an increased risk of clot pathway activation that may eventually provoke thrombosis and pregnancy loss. Considering that antimalarials do not have major bleeding side-effects,<sup><xref ref-type="bibr" rid="bibr52-0961203312465782">52</xref></sup> and although there is limited clinical evidence for their efficacy in APS, they have been recommended as adjunct therapy together with LDA and prophylactic LMWH. Further controlled studies are required to establish their safety profile and efficacy in the management of refractory OAPS.</p>
</sec>
<sec id="sec12-0961203312465782"><title>Double anti-aggregant schedule</title>
<p>A combination of dipyridamole – an adenosine uptake inhibitor – and LDA has proven useful in patients with stroke,<sup><xref ref-type="bibr" rid="bibr77-0961203312465782">77</xref></sup> even with stroke related to APS.<sup><xref ref-type="bibr" rid="bibr78-0961203312465782">78</xref></sup> Furthermore, in vitro dipyridamole is able to inhibit TF expression on monocytes induced by aPL–IgG from patients with APS.<sup><xref ref-type="bibr" rid="bibr79-0961203312465782">79</xref></sup> Dipyridamole may also improve the balance between angiogenic/anti-angiogenic factors in placental tissue.<sup><xref ref-type="bibr" rid="bibr80-0961203312465782">80</xref></sup> Double anti-aggregant schema could be of interest by avoiding the platelet activation pathway, and further complete clot formation, as well as by blocking monocyte activation in APS patients. When combined with other molecules dipyridamole has been used in cases of stroke related to APS<sup><xref ref-type="bibr" rid="bibr78-0961203312465782">78</xref></sup> as well as in cases of CAPS.<sup><xref ref-type="bibr" rid="bibr81-0961203312465782">81</xref>,<xref ref-type="bibr" rid="bibr82-0961203312465782">82</xref></sup> As fetal abnormalities have not been observed in pregnant women treated with double anti-aggregant therapy,<sup><xref ref-type="bibr" rid="bibr80-0961203312465782">80</xref></sup> either alone or in combination with other drugs, this could offer a novel therapeutic approach in refractory OAPS.</p>
</sec>
<sec id="sec13-0961203312465782"><title>Corticosteroids</title>
<p>The role of corticosteroids for refractory OAPS has been studied for over 30 years.<sup><xref ref-type="bibr" rid="bibr83-0961203312465782">83</xref></sup> Corticosteroids block diverse immune pathways, one of them being the inhibition of complement pathway activation, both in vitro and in vivo.<sup><xref ref-type="bibr" rid="bibr84-0961203312465782">84</xref>,<xref ref-type="bibr" rid="bibr85-0961203312465782">85</xref></sup> Some years ago, Quenby et al.<sup><xref ref-type="bibr" rid="bibr86-0961203312465782">86</xref></sup> suggested the beneficial potential of corticosteroids in women with recurrent miscarriages, owing to their ability to reduce the number of NK cells. Recently, Bramham et al.<sup><xref ref-type="bibr" rid="bibr87-0961203312465782">87</xref></sup> published their results in a cohort of women with refractory OAPS treated with early low-dose prednisolone in addition to LDA and heparin, who achieved 61% live births. Interestingly, there was no evidence of maternal morbidity in that series. However, large doses of corticosteroids (0.5–1 mg/kg daily) have been associated with an increased risk of gestational diabetes, infections, pregnancy-induced hypertension and preterm deliveries.<sup><xref ref-type="bibr" rid="bibr88-0961203312465782">88</xref></sup> These adverse effects appear to be absent when low prednisone or prednisolone doses are used (10–20 mg/kg daily).<sup><xref ref-type="bibr" rid="bibr86-0961203312465782">86</xref>,<xref ref-type="bibr" rid="bibr87-0961203312465782">87</xref></sup> High-dose glucocorticoids are broadly disregarded as a treatment option. The real effectiveness of low-corticosteroid doses administered in the first trimester of gestation is currently under investigation.<sup><xref ref-type="bibr" rid="bibr8-0961203312465782">8</xref>,<xref ref-type="bibr" rid="bibr87-0961203312465782">87</xref></sup> The metabolism of non-fluorinated glucocorticoids by the placenta ensures that only 10% of inactive metabolites cross the placenta to the fetal circulation at maternal doses of less than 20 mg.<sup><xref ref-type="bibr" rid="bibr87-0961203312465782">87</xref>,<xref ref-type="bibr" rid="bibr89-0961203312465782">89</xref></sup> A recent in vitro study provided more data on the possible use of corticosteroids in the down-regulation of maternal–fetal immune response. One of the leading mechanisms regulating maternal immune-tolerance to fetal antigens is the expression of an unusual combination of human leukocyte antigens (HLA), i.e. HLA-C, HLA-E and HLA-G, in trophoblast cells.<sup><xref ref-type="bibr" rid="bibr36-0961203312465782">36</xref></sup> Altered HLA-G expression on extravillous cytotrophoblast has been related to recurrent miscarriages. In this regard, Akther et al.<sup><xref ref-type="bibr" rid="bibr90-0961203312465782">90</xref></sup> have shown that glucocorticoids are able to up-regulate HLA-G expression in trophoblast cells, in a dose-dependent manner. Thus, it may be useful to study whether or not glucocorticoids have the potential to modulate HLA-G in vitro, given their therapeutic role in recurrent miscarriages and in refractory APS.</p>
</sec>
<sec id="sec14-0961203312465782"><title>Intravenous immunoglobulins</title>
<p>Intravenous immunoglobulins (IVIGs) are being used in some autoimmune-mediated diseases, with varying degrees of success.<sup><xref ref-type="bibr" rid="bibr91-0961203312465782">91</xref></sup> IVIGs have also been administered in cases of idiopathic recurrent miscarriages, also with conflicting results,<sup><xref ref-type="bibr" rid="bibr92-0961203312465782">92</xref>,<xref ref-type="bibr" rid="bibr93-0961203312465782">93</xref></sup> In the field of aPL-related disorders, IVIGs have been included in the therapeutic schema of severe thrombocytopenia and in CAPS.<sup><xref ref-type="bibr" rid="bibr94-0961203312465782">94</xref></sup> Currently, however, no data on the usefulness of IVIG in OAPS are available, owing to their relatively high cost and short supply.<sup><xref ref-type="bibr" rid="bibr95-0961203312465782">95</xref></sup> The few published studies and meta-analyses available concluded that no benefits are observed when IVIGs are given in association with LDA plus LMWH, compared to LDA plus LMWH alone.<sup><xref ref-type="bibr" rid="bibr96-0961203312465782">96</xref>–<xref ref-type="bibr" rid="bibr99-0961203312465782">99</xref></sup> However, other data<sup><xref ref-type="bibr" rid="bibr100-0961203312465782">100</xref></sup> including one controlled study<sup><xref ref-type="bibr" rid="bibr101-0961203312465782">101</xref></sup> reported positive results. We now know some of the mechanisms involved in PL-related placental injury, which can be blocked by immunoglobulin infusion.<sup><xref ref-type="bibr" rid="bibr102-0961203312465782">102</xref></sup> In addition, a subpopulation of women with NK cell expansion could be a select subset for IVIG-targeted therapy.<sup><xref ref-type="bibr" rid="bibr103-0961203312465782">103</xref></sup> Furthermore, our understanding of the pharmacokinetics of IVIG use before and during pregnancy in healthy women with poor obstetrical histories is improving, rendering their use more rational and safer.<sup><xref ref-type="bibr" rid="bibr104-0961203312465782">104</xref></sup> Although more well-designed studies are required to ascertain the true role played by IVIGs in OAPS, a rationale exists for their use in selected cases of women with refractory OAPS.</p>
</sec>
<sec id="sec15-0961203312465782"><title>Biologic therapy: TNF-targeted therapies</title>
<p>TNF-targeted therapies are increasingly used for a rapidly expanding number of rheumatic and autoimmune diseases. TNF-alpha is a cytokine which plays a crucial role in causing inflammation by means of predominantly T-cell-mediated tissue damage.<sup><xref ref-type="bibr" rid="bibr105-0961203312465782">105</xref>,<xref ref-type="bibr" rid="bibr106-0961203312465782">106</xref></sup> As previously mentioned, TNF-alpha appears to be a critical effector in aPL-related placental injury and further miscarriage.<sup><xref ref-type="bibr" rid="bibr27-0961203312465782">27</xref>,<xref ref-type="bibr" rid="bibr46-0961203312465782">46</xref></sup> The three most commonly used anti-TNF-alpha drugs are infliximab, etanercept and adalimumab. Infliximab is a chimeric monoclonal antibody against TNF-alpha administered as an intravenous infusion. Etanercept, a p75 TNF-receptor fusion protein conjugated to the Fc region of human IgG immunoglobulin, is administered as a subcutaneous injection twice weekly. Adalimumab is a human anti-TNF monoclonal antibody also administered subcutaneously every two weeks. These three agents have been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) for the treatment of certain rheumatic, digestive and cutaneous immune-mediated diseases.<sup><xref ref-type="bibr" rid="bibr106-0961203312465782">106</xref>,<xref ref-type="bibr" rid="bibr107-0961203312465782">107</xref></sup> All these drugs were tested involuntarily in women with inflammatory diseases who become pregnant whilst under TNF-targeted treatment, and no significant fetal adverse effects were observed.<sup><xref ref-type="bibr" rid="bibr108-0961203312465782">108</xref>–<xref ref-type="bibr" rid="bibr110-0961203312465782">110</xref></sup> Nevertheless, anti-TNF drugs are still classified by the FDA as ‘pregnancy risk category B’, since human studies are still insufficient to guarantee their absolute safety for the fetus, although adverse effects have not been observed in either small human series or in animal pregnancies.<sup><xref ref-type="bibr" rid="bibr108-0961203312465782">108</xref>,<xref ref-type="bibr" rid="bibr111-0961203312465782">111</xref></sup> Possible infectious and autoimmune reactions have, however, been reported in patients treated with TNF-targeted therapies,<sup><xref ref-type="bibr" rid="bibr106-0961203312465782">106</xref>,<xref ref-type="bibr" rid="bibr112-0961203312465782">112</xref></sup> including two cases of ‘de novo’ APS reported in a large Spanish cohort.<sup><xref ref-type="bibr" rid="bibr106-0961203312465782">106</xref></sup> These autoimmune reactions usually resolve when anti-TNF drugs are withdrawn.</p>
<p>Adalimumab<sup><xref ref-type="bibr" rid="bibr113-0961203312465782">113</xref>,<xref ref-type="bibr" rid="bibr114-0961203312465782">114</xref></sup> and etanercept<sup><xref ref-type="bibr" rid="bibr115-0961203312465782">115</xref>,<xref ref-type="bibr" rid="bibr116-0961203312465782">116</xref></sup> have been used to treat women with recurrent miscarriages or repeated in vitro fertilization (IVF) failure, both with good results. To my knowledge, no reports have been published regarding the use of anti-TNF drugs in women with OAPS. Although well-designed studies regarding the safety and effectiveness of this family of drugs should, of course, be conducted, I believe that anti-TNF-alpha blockers, particularly etanercept and adalimumab, could be useful in selected refractory cases of OAPS.</p>
</sec>
<sec id="sec16-0961203312465782"><title>Other immune-modulatory / anti-inflammatory drugs</title>
<sec id="sec17-0961203312465782"><title>Pentoxifylline</title>
<p>Pentoxifylline is a phosphodiesterase inhibitor commonly used in the treatment of peripheral vascular disease. A wide range of immunomodulatory properties has been described, including the down-regulation of TNF-alpha synthesis.<sup><xref ref-type="bibr" rid="bibr116-0961203312465782">116</xref></sup> Furthermore, animal models have shown a reduction in fetal resorption, thereby diminishing the levels of TNF-alpha and increasing those of IL-10 and IL-4 produced placentally.<sup><xref ref-type="bibr" rid="bibr117-0961203312465782">117</xref>,<xref ref-type="bibr" rid="bibr118-0961203312465782">118</xref></sup></p>
<p>Similarly, pentoxifylline has shown positive effects in diverse situations such as cardiomyopathies<sup><xref ref-type="bibr" rid="bibr119-0961203312465782">119</xref></sup> and endometriosis-related infertility.<sup><xref ref-type="bibr" rid="bibr120-0961203312465782">120</xref>,<xref ref-type="bibr" rid="bibr121-0961203312465782">121</xref></sup> It had been used previously in the treatment of certain forms of thrombotic APS.<sup><xref ref-type="bibr" rid="bibr122-0961203312465782">122</xref></sup> Given its ability to modify the Th1/Th2 cytokine balance, together with its lack of adverse effects, pentoxifylline may prove to be another useful drug in refractory OAPS. Moreover, Letur-Konirsch and Delanian<sup><xref ref-type="bibr" rid="bibr123-0961203312465782">123</xref></sup> showed that, in women with premature ovarian syndrome and uterine resistance to hormone replacement therapy (HRT), combined pentoxifylline plus tocopherol treatment reduces uterine lesions and improves the uterine response to HRT, thus facilitating embryo implantation and ongoing pregnancy.</p>
</sec>
<sec id="sec18-0961203312465782"><title>Coenzyme Q10</title>
<p>APS produces alterations in oxidative stress owing to mitochondrial dysfunction. Atherosclerosis associated with APS could therefore be related to increases in oxidative enzymatic activity. Perez-Sanchez et al.<sup><xref ref-type="bibr" rid="bibr124-0961203312465782">124</xref></sup> reported that APS patients showed an increase in oxidative stress which could be prevented and/or reversed by treatment with coenzyme Q10.</p>
<p>Further studies will be needed to demonstrate the possible benefits of coenzyme Q10 administration in APS.</p>
</sec>
<sec id="sec19-0961203312465782"><title>Vitamin D</title>
<p>Vitamin D is no longer regarded only as a vitamin essential for calcium and bone metabolism, but also as a molecule modulating the immune response.<sup><xref ref-type="bibr" rid="bibr125-0961203312465782">125</xref></sup>. A close alliance has been observed between vitamin D and autoimmunity, both in experimental models and in humans, mainly in rheumatoid arthritis, SLE, thyroid diseases, multiple sclerosis and type 1 diabetes.<sup><xref ref-type="bibr" rid="bibr126-0961203312465782">126</xref></sup> As previously mentioned, TF over-expression related to aPL plays a crucial role in coagulation pathway activation.<sup><xref ref-type="bibr" rid="bibr46-0961203312465782">46</xref>,<xref ref-type="bibr" rid="bibr58-0961203312465782">58</xref>,<xref ref-type="bibr" rid="bibr127-0961203312465782">127</xref></sup> Activation of endothelial cells by aPL-activated monocytes, mainly anti-β2GP I, results in over-expression of TF and adhesion molecules, thereby contributing to the development of inflammation and thrombosis.<sup><xref ref-type="bibr" rid="bibr128-0961203312465782">128</xref></sup> Monocyte activation has recently been shown to be dependent on Toll-like receptor (TLR)-4 signalling.<sup><xref ref-type="bibr" rid="bibr129-0961203312465782">129</xref></sup> Interestingly, vitamin D is able to suppress the expression of TLRs such as TLR-4.<sup><xref ref-type="bibr" rid="bibr130-0961203312465782">130</xref></sup></p>
<p>Agmon-Levin et al.<sup><xref ref-type="bibr" rid="bibr126-0961203312465782">126</xref></sup> found low vitamin D levels in APS patients, and associated them with thrombotic complaints. These authors also showed, in vitro, that vitamin D exerted its anti-thrombotic effect via inhibition of endothelial cell TF expression. Unfortunately, although women with obstetric APS also had low vitamin levels, the authors found no correlation with obstetrical complications. Overall, these data support a potential beneficial effect of vitamin D supplementation in APS and refractory OAPS, in combination with the recommended therapeutic regimens.</p>
</sec>
</sec>
<sec id="sec20-0961203312465782"><title>Other drugs</title>
<p>Dilacept (an adenosine uptake inhibitor, similar to dipyridamole),<sup><xref ref-type="bibr" rid="bibr131-0961203312465782">131</xref></sup> defibrotide (a single-stranded DNA derivate),<sup><xref ref-type="bibr" rid="bibr132-0961203312465782">132</xref></sup> angiotensin-converting enzyme inhibitors<sup><xref ref-type="bibr" rid="bibr133-0961203312465782">133</xref></sup> and histone deacetylase inhibitors<sup><xref ref-type="bibr" rid="bibr134-0961203312465782">134</xref></sup> act to inhibit endothelial or monocyte TF expression.<sup><xref ref-type="bibr" rid="bibr135-0961203312465782">135</xref></sup> In the same way, the use of statins, which have pleiotropic anti-inflammatory and immunomodulating properties, as well as complement-targeted drugs and TLRs-blocking molecules<sup><xref ref-type="bibr" rid="bibr136-0961203312465782">136</xref></sup> is potentially supported by a similar rationale. However, there are as yet no data related to their effectiveness in women with OAPS, and their use during pregnancy is still to be tested.</p>
</sec>
</sec>
<sec id="sec21-0961203312465782" sec-type="conclusions"><title>Conclusions</title>
<p>Although a recent paper, not designed as a treatment trial, questions the effectiveness of heparin in women with adverse pregnancy outcomes related to aPL,<sup><xref ref-type="bibr" rid="bibr137-0961203312465782">137</xref></sup> the currently accepted first-line treatment of OAPS includes LDA plus prophylactic unfractionated or LMWH. As yet, in approximately 20% of cases, live births cannot be achieved. This is a challenging situation that has to be managed carefully by physicians since there are no definitive data regarding this clinical situation. An improved understanding of the pathogenesis of OAPS, which includes thrombotic, and particularly non-thrombotic, underlying inflammatory mechanisms, and the pleiotropic properties of certain drugs, may yield new therapeutic approaches. These new strategies include starting LDA and heparin as soon as possible and maybe choosing the most useful LMWH or fondaparinux. The possibility of adding hydroxychloroquine and/or low-dose prednisolone should be carefully considered in these refractory cases. Should obstetric success not be obtained, other approaches could be attempted. TNF-targeting drugs have been tried with success in cases of idiopathic recurrent miscarriages and in women with recurrent in vitro fertilization failure. Neither maternal nor fetal adverse events have been reported. Thus, TNF-targeting drugs combined with LAD plus LMWH plus hydroxychloroquine or low-dose prednisolone maybe a rational option for selected cases. Finally, in the remaining cases who do not respond to these therapeutic regimens, a trial of IVIG could be conducted. As most of these proposed therapeutic regimens have to be considered as experimental, prospective, well-designed trials should be carried out before their use can be generalized (<xref ref-type="table" rid="table3-0961203312465782">Table 3</xref>).
<table-wrap id="table3-0961203312465782" position="float"><label>Table 3</label><caption><p>New possible therapeutic steps<sup><xref ref-type="table-fn" rid="table-fn6-0961203312465782">a</xref></sup> to be tried for treating refractory obstetric antiphospholipid syndrome</p></caption>
<graphic alternate-form-of="table3-0961203312465782" xlink:href="10.1177_0961203312465782-table3.tif"/>
<table frame="hsides">
<tbody align="left">
<tr>
<td>Step 1:</td>
</tr>
<tr>
<td>LDA started minimum 4 weeks before gestation</td>
</tr>
<tr>
<td>Start LMWH as soon as possible – in early stages of pregnancy</td>
</tr>
<tr>
<td>Change enoxaparin for other similar compound, i.e. tinzaparin or fondaparinux</td>
</tr>
<tr>
<td>Vitamin D supplementation</td>
</tr>
<tr>
<td>Step 2: Step 1 plus</td>
</tr>
<tr>
<td>Hydroxychloroquine or low-dose prednisolone (10–15 mg/day)</td>
</tr>
<tr>
<td>Step 3: Step 1 plus</td>
</tr>
<tr>
<td>Hydroxychloroquine plus low-dose prednisolone and/or pentoxifylline</td>
</tr>
<tr>
<td>Step 4: Add new TNF-targeting drugs<sup><xref ref-type="table-fn" rid="table-fn7-0961203312465782">b</xref></sup></td>
</tr>
<tr>
<td>Step 5: Add IVIG</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0961203312465782"><p>LDA: low-dose aspirin; LMWH: low-molecular-weight heparin; IVIG: intravenous immunoglobulin</p></fn>
<fn id="table-fn6-0961203312465782"><label>a</label><p>The therapeutic steps should be studied in well-designed clinical trials before their use is generalized. In the future, populations stratified for vitamin D levels, number of natural killer cells, protein complement analysis, and particularly, different antiphospholipid antibodies classes could suggest which drugs are added to the LDA + LMWH regimen.</p></fn>
<fn id="table-fn7-0961203312465782"><label>b</label><p>Infliximab, etanercept and adalimumab.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
</body>
<back>
<sec id="sec22-0961203312465782"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec23-0961203312465782"><title>Conflict of interest statement</title>
<p>The author declares he does not have any competing interest.</p>
</sec>
<notes>
<title>Note</title>
<fn-group>
<fn id="fn1-1468017311431476"><p>The authors thank Mrs Christine O’Hara for reviewing and correcting the style and grammar of the manuscript.</p></fn></fn-group></notes>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312465782"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Noriyuki</surname><given-names>N</given-names></name><name><surname>Kaburaki</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Excessive exposure to anionic surfaces maintains autoantibody response to B2-glycoprotein I in patients with antiphospholipid syndrome</article-title>. <source>Blood</source> <year>2007</year>; <volume>110</volume>: <fpage>4312</fpage>–<lpage>4318</lpage>.</citation></ref>
<ref id="bibr2-0961203312465782"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyakis</surname><given-names>S</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome</article-title>. <source>J Thromb Haemost</source> <year>2006</year>; <volume>4</volume>: <fpage>295</fpage>–<lpage>306</lpage>.</citation></ref>
<ref id="bibr3-0961203312465782"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alijotas-Reig</surname><given-names>J</given-names></name></person-group>. <article-title>Towards the comprehension of the heterogeneity of clinical manifestations related with antiphospholipid antibodies</article-title>. <source>Med Clin [Barc]</source> <year>2005</year>; <volume>125</volume>: <fpage>187</fpage>–<lpage>189</lpage>.</citation></ref>
<ref id="bibr4-0961203312465782"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boffa</surname><given-names>M-C</given-names></name><name><surname>Boinot</surname><given-names>C</given-names></name><name><surname>de Carolis</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Laboratory criteria of the obstetrical antiphospholipid syndrome [APS]. Data from a multicentre prospective European women cohort</article-title>. <source>Thromb Haemost</source> <year>2009</year>; <volume>102</volume>: <fpage>25</fpage>–<lpage>28</lpage>.</citation></ref>
<ref id="bibr5-0961203312465782"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meroni</surname><given-names>P</given-names></name><name><surname>Raschi</surname><given-names>E</given-names></name><name><surname>Grossi</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Obstetric and vascular APS: Same autoantibodies but different diseases?</article-title> <source>Lupus</source> <year>2012</year>; <volume>21</volume>: <fpage>708</fpage>–<lpage>710</lpage>.</citation></ref>
<ref id="bibr6-0961203312465782"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lassere</surname><given-names>M</given-names></name><name><surname>Empson</surname><given-names>M</given-names></name></person-group>. <article-title>Treatment of antiphospholipid syndrome in pregnancy – a systematic review of randomized therapeutic trials</article-title>. <source>Thromb Res</source> <year>2004</year>; <volume>114</volume>: <fpage>419</fpage>–<lpage>426</lpage>.</citation></ref>
<ref id="bibr7-0961203312465782"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danza</surname><given-names>A</given-names></name><name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name></person-group>. <article-title>Antiphospholipid syndrome in obstetrics</article-title>. <source>Best Pract Res Clin Obstet Gynecol</source> <year>2012</year>; <volume>26</volume>: <fpage>65</fpage>–<lpage>76</lpage>.</citation></ref>
<ref id="bibr8-0961203312465782"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scoble</surname><given-names>T</given-names></name><name><surname>Wijetilleka</surname><given-names>S</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name></person-group>. <article-title>Management of refractory anti-phospholipid syndrome</article-title>. <source>Autoimmunity Rev</source> <year>2011</year>; <volume>10</volume>: <fpage>669</fpage>–<lpage>673</lpage>.</citation></ref>
<ref id="bibr9-0961203312465782"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>SM</given-names></name></person-group>. <article-title>Consultative hematology: the pregnant patient pregnancy loss</article-title>. <source>Haematology Am Soc Hematol Educ Program</source> <year>2010</year>; <volume>2010</volume>: <fpage>166</fpage>–<lpage>172</lpage>.</citation></ref>
<ref id="bibr10-0961203312465782"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simchen</surname><given-names>MJ</given-names></name><name><surname>Dulitzki</surname><given-names>M</given-names></name><name><surname>Rofe</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome</article-title>. <source>Acta Obstet Gynecol Scand</source> <year>2011</year>; <volume>90</volume>: <fpage>1428</fpage>–<lpage>1433</lpage>.</citation></ref>
<ref id="bibr11-0961203312465782"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Prima</surname><given-names>FAF</given-names></name><name><surname>Valenti</surname><given-names>O</given-names></name><name><surname>Hyseni</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Antiphospholipid syndrome during pregnancy: the state of the art</article-title>. <source>J Perinatal Med</source> <year>2011</year>; <volume>5</volume>: <fpage>41</fpage>–<lpage>53</lpage>.</citation></ref>
<ref id="bibr12-0961203312465782"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alijotas-Reig</surname><given-names>J</given-names></name><name><surname>Ferrer-Oliveras</surname><given-names>R</given-names></name></person-group>. <article-title>The European Registry on Obstetric Antiphospholipid Syndrome [EUROAPS]: A preliminary first year report</article-title>. <source>Lupus</source> <year>2012</year>; <volume>21</volume>: <fpage>766</fpage>–<lpage>768</lpage>.</citation></ref>
<ref id="bibr13-0961203312465782"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Jesus</surname><given-names>GR</given-names></name><name><surname>dos Santos</surname><given-names>FC</given-names></name><name><surname>Oliveira</surname><given-names>CS</given-names></name><etal/></person-group>. <article-title>Management of obstetric antiphospholipid syndrome</article-title>. <source>Curr Rheumatol Rep</source> <year>2012</year>; <volume>14</volume>: <fpage>79</fpage>–<lpage>86</lpage>.</citation></ref>
<ref id="bibr14-0961203312465782"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Berger</surname><given-names>SP</given-names></name><name><surname>Steup-Beekman</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Diagnosis and management of antiphospholipid syndrome</article-title>. <source>BMJ</source> <year>2010</year>; <volume>340</volume>: <fpage>1125</fpage>–<lpage>1132</lpage>.</citation></ref>
<ref id="bibr15-0961203312465782"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name><name><surname>Egurbide</surname><given-names>MV</given-names></name><name><surname>Ugalde</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus</article-title>. <source>Arch Intern Med</source> <year>2004</year>; <volume>164</volume>: <fpage>77</fpage>–<lpage>78</lpage>.</citation></ref>
<ref id="bibr16-0961203312465782"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Iratorza</surname><given-names>G</given-names></name><name><surname>Crowther</surname><given-names>M</given-names></name><name><surname>Branch</surname><given-names>W</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name></person-group>. <article-title>Antiphospholipid syndrome</article-title>. <source>Lancet</source> <year>2010</year>; <volume>376</volume>: <fpage>1498</fpage>–<lpage>1509</lpage>.</citation></ref>
<ref id="bibr17-0961203312465782"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drakeley</surname><given-names>AJ</given-names></name><name><surname>Quenby</surname><given-names>S</given-names></name><name><surname>Farquharson</surname><given-names>R</given-names></name></person-group>. <article-title>Mid-trimester loss – appraisal of a screening protocol</article-title>. <source>Hum Reprod</source> <year>1998</year>; <volume>13</volume>: <fpage>1975</fpage>–<lpage>1980</lpage>.</citation></ref>
<ref id="bibr18-0961203312465782"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galarza-Maldonado</surname><given-names>C</given-names></name><name><surname>Kourilovitch</surname><given-names>MA</given-names></name><name><surname>Perez-Fernandez</surname><given-names>OM</given-names></name><etal/></person-group>. <article-title>Obstetric antiphospholipid syndrome</article-title>. <source>Autoimmun Rev</source> <year>2012</year>; <volume>11</volume>: <fpage>288</fpage>–<lpage>295</lpage>.</citation></ref>
<ref id="bibr19-0961203312465782"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Piette</surname><given-names>JC</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Antiphospholipid syndrome: clinical and immunologic manifestations and pattern of disease expression in a cohort of 1,000 patients</article-title>. <source>Arthritis Rheum</source> <year>2002</year>; <volume>46</volume>: <fpage>1019</fpage>–<lpage>1027</lpage>.</citation></ref>
<ref id="bibr20-0961203312465782"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrer-Oliveras</surname><given-names>R</given-names></name><name><surname>Llurba</surname><given-names>E</given-names></name><name><surname>Cabero-Roura</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Prevalence and clinical usefulness of antiphospholipid and anti-cofactor antibodies in different Spanish preeclampsia subsets</article-title>. <source>Lupus</source> <year>2012</year>; <volume>21</volume>: <fpage>257</fpage>–<lpage>263</lpage>.</citation></ref>
<ref id="bibr21-0961203312465782"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Puerta</surname><given-names>JA</given-names></name><name><surname>Sanin-Blair</surname><given-names>J</given-names></name><name><surname>Galarza-Maldonado</surname><given-names>C</given-names></name></person-group>. <article-title>Pregnancy and catastrophic antiphospholipid syndrome</article-title>. <source>Clin Rev Allergy Immunol</source> <year>2009</year>; <volume>36</volume>: <fpage>85</fpage>–<lpage>90</lpage>.</citation></ref>
<ref id="bibr22-0961203312465782"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meroni</surname><given-names>PL</given-names></name></person-group>. <article-title>Endothelial cell perturbation by anti-phospholipid antibodies in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2007</year>; <volume>16</volume>(<issue>suppl</issue>): <fpage>17</fpage>–<lpage>19</lpage>.</citation></ref>
<ref id="bibr23-0961203312465782"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname><given-names>T</given-names></name></person-group>. <article-title>Antiphospholipid antibodies and cell activation</article-title>. <source>Lupus</source> <year>2007</year>; <volume>16</volume>(<issue>suppl</issue>): <fpage>17</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr24-0961203312465782"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>Borghi</surname><given-names>MO</given-names></name><name><surname>Raschi</surname><given-names>E</given-names></name><name><surname>Ventura</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Inflammatory response and the endothelium</article-title>. <source>Thromb Res</source> <year>2004</year>; <volume>114</volume>: <fpage>329</fpage>–<lpage>334</lpage>.</citation></ref>
<ref id="bibr25-0961203312465782"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asherson</surname><given-names>RA</given-names></name><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Wells</surname><given-names>AU</given-names></name></person-group>. <article-title>Diffuse alveolar haemorrhage: a non-thrombotic antiphospholipid lung syndrome?</article-title> <source>Semin Arthritis Rheum</source> <year>2005</year>; <volume>35</volume>: <fpage>138</fpage>–<lpage>142</lpage>.</citation></ref>
<ref id="bibr26-0961203312465782"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asherson</surname><given-names>RA</given-names></name><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Shepshelovich</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Non-thrombotic manifestations of the antiphospholipid syndrome: away from thrombosis?</article-title> <source>J Rheumatol</source> <year>2006</year>; <volume>33</volume>: <fpage>1038</fpage>–<lpage>1044</lpage>.</citation></ref>
<ref id="bibr27-0961203312465782"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alijotas-Reig</surname><given-names>J</given-names></name><name><surname>Vilardell-Tarrés</surname><given-names>M</given-names></name></person-group>. <article-title>Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?</article-title> <source>Obstet Gynecol Surv</source> <year>2010</year>; <volume>65</volume>: <fpage>39</fpage>–<lpage>45</lpage>.</citation></ref>
<ref id="bibr28-0961203312465782"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Out</surname><given-names>HJ</given-names></name><name><surname>Kooijman</surname><given-names>CD</given-names></name><name><surname>Bruinse</surname><given-names>HW</given-names></name><etal/></person-group>. <article-title>Histopathological findings in placenta from patients with intra-uterine fetal death and antiphospholipid antibodies</article-title>. <source>Eur J Obstet Gynaecol Reprod Biol</source> <year>1991</year>; <volume>195</volume>: <fpage>211</fpage>–<lpage>220</lpage>.</citation></ref>
<ref id="bibr29-0961203312465782"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girardi</surname><given-names>G</given-names></name><name><surname>Redecha</surname><given-names>P</given-names></name><name><surname>Salmon</surname><given-names>JE</given-names></name></person-group>. <article-title>Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation</article-title>. <source>Nature Med</source> <year>2004</year>; <volume>10</volume>: <fpage>1222</fpage>–<lpage>1226</lpage>.</citation></ref>
<ref id="bibr30-0961203312465782"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girardi</surname><given-names>G</given-names></name><name><surname>Berman</surname><given-names>J</given-names></name><name><surname>Redecha</surname><given-names>P</given-names></name></person-group>. <article-title>Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome</article-title>. <source>J Clin Invest</source> <year>2003</year>; <volume>112</volume>: <fpage>1644</fpage>–<lpage>1654</lpage>.</citation></ref>
<ref id="bibr31-0961203312465782"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holers</surname><given-names>VM</given-names></name><name><surname>Girardi</surname><given-names>G</given-names></name><name><surname>Mo</surname><given-names>L</given-names></name></person-group>. <article-title>Complement C3 activation is required for antiphospholipid antibody induced fetal loss</article-title>. <source>J Exp Med</source> <year>2002</year>; <volume>195</volume>: <fpage>211</fpage>–<lpage>220</lpage>.</citation></ref>
<ref id="bibr32-0961203312465782"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>di Simone</surname><given-names>N</given-names></name><name><surname>Testoni</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Antiphospholipid antibodies as cause of pregnancy loss</article-title>. <source>Lupus</source> <year>2004</year>; <volume>13</volume>: <fpage>649</fpage>–<lpage>652</lpage>.</citation></ref>
<ref id="bibr33-0961203312465782"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magid</surname><given-names>MS</given-names></name><name><surname>Kaplan</surname><given-names>C</given-names></name><name><surname>Sammaritano</surname><given-names>LR</given-names></name><etal/></person-group>. <article-title>Placental pathology in systemic lupus erythematosus: a prospective study</article-title>. <source>Am J Obstet Gynecol</source> <year>1998</year>; <volume>179</volume>: <fpage>226</fpage>–<lpage>234</lpage>.</citation></ref>
<ref id="bibr34-0961203312465782"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>CH</given-names></name><name><surname>Simpson</surname><given-names>KL</given-names></name></person-group>. <article-title>Complement and pregnancy: new insights into the immunobiology of the fetal-maternal relationship</article-title>. <source>Balliere’s Clin Obstet Gynecol</source> <year>1992</year>; <volume>6</volume>: <fpage>439</fpage>–<lpage>459</lpage>.</citation></ref>
<ref id="bibr35-0961203312465782"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>DS</given-names></name><name><surname>Tichenor</surname><given-names>JR</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Decay-accelerating factor protects human trophoblast from complement-mediated attack</article-title>. <source>Clin Immunol Immunopathol</source> <year>1995</year>; <volume>74</volume>: <fpage>156</fpage>–<lpage>161</lpage>.</citation></ref>
<ref id="bibr36-0961203312465782"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alijotas-Reig</surname><given-names>J</given-names></name></person-group>. <article-title>The immunological puzzle of recurrent miscarriage</article-title>. <source>Curr Immunol Rev</source> <year>2009</year>; <volume>5</volume>: <fpage>175</fpage>–<lpage>186</lpage>.</citation></ref>
<ref id="bibr37-0961203312465782"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quenby</surname><given-names>S</given-names></name><name><surname>Bates</surname><given-names>M</given-names></name><name><surname>Doig</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Pre-implantation endometrial leukocytes in women with recurrent miscarriage</article-title>. <source>Hum Reprod</source> <year>1999</year>; <volume>14</volume>: <fpage>2386</fpage>–<lpage>2391</lpage>.</citation></ref>
<ref id="bibr38-0961203312465782"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuckerman</surname><given-names>E</given-names></name><name><surname>Laird</surname><given-names>S</given-names></name><name><surname>Prakash</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Prognostic value of the measurement of uterine natural killer cells in the endometrium of women with recurrent miscarriage</article-title>. <source>Hum Reprod</source> <year>2007</year>; <volume>22</volume>: <fpage>2208</fpage>–<lpage>2213</lpage>.</citation></ref>
<ref id="bibr39-0961203312465782"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szekeres-Bartho</surname><given-names>J</given-names></name><name><surname>Faust</surname><given-names>Z</given-names></name><name><surname>Varga</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production</article-title>. <source>Am J Reprod Immunol</source> <year>1996</year>; <volume>35</volume>: <fpage>348</fpage>–<lpage>351</lpage>.</citation></ref>
<ref id="bibr40-0961203312465782"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carp</surname><given-names>HJA</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells - an additional mechanism in a multifactorial process</article-title>. <source>Rheumatology</source> <year>2007</year>; <volume>46</volume>: <fpage>1517</fpage>–<lpage>1519</lpage>.</citation></ref>
<ref id="bibr41-0961203312465782"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>Ten Cate</surname><given-names>H</given-names></name></person-group>. <article-title>Disseminated intravascular coagulation</article-title>. <source>N Engl J Med</source> <year>1999</year>; <volume>42</volume>: <fpage>71</fpage>–<lpage>75</lpage>.</citation></ref>
<ref id="bibr42-0961203312465782"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szekeres-Bartho</surname><given-names>J</given-names></name><name><surname>Kilar</surname><given-names>F</given-names></name><name><surname>Falkay</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>The mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity: I. Progesterone-treated lymphocytes of healthy pregnant women release a factor inhibiting cytotoxicity and prostaglandin synthesis</article-title>. <source>Am J Reprod Immunol Microbiol</source> <year>1985</year>; <volume>9</volume>: <fpage>15</fpage>–<lpage>19</lpage>.</citation></ref>
<ref id="bibr43-0961203312465782"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faust</surname><given-names>Z</given-names></name><name><surname>Laskarin</surname><given-names>G</given-names></name><name><surname>Rukavina</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Progesterone induced blocking factor inhibits degranulation of NK cells</article-title>. <source>Am J Reprod Immunol</source> <year>1999</year>; <volume>42</volume>: <fpage>71</fpage>–<lpage>75</lpage>.</citation></ref>
<ref id="bibr44-0961203312465782"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carp</surname><given-names>HJA</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells-an additional mechanism in a multifactorial process</article-title>. <source>Rheumatology</source> <year>2007</year>; <volume>46</volume>: <fpage>1517</fpage>–<lpage>1519</lpage>.</citation></ref>
<ref id="bibr45-0961203312465782"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perricone</surname><given-names>C</given-names></name><name><surname>De Carolis</surname><given-names>C</given-names></name><name><surname>Giaccomelli</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis</article-title>. <source>Rheumatology</source> <year>2007</year>; <volume>46</volume>: <fpage>1574</fpage>–<lpage>1578</lpage>.</citation></ref>
<ref id="bibr46-0961203312465782"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>J</given-names></name><name><surname>Girardi</surname><given-names>G</given-names></name><name><surname>Salmon</surname><given-names>JE</given-names></name></person-group>. <article-title>TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss</article-title>. <source>J Immunol</source> <year>2005</year>; <volume>174</volume>: <fpage>1222</fpage>–<lpage>1226</lpage>.</citation></ref>
<ref id="bibr47-0961203312465782"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>Borghi</surname><given-names>MO</given-names></name><name><surname>Raschi</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Pathogenesis of antiphospholipid syndrome: understanding the antibodies</article-title>. <source>Nat Rev Rheumatol</source> <year>2011</year>; <volume>7</volume>: <fpage>330</fpage>–<lpage>339</lpage>.</citation></ref>
<ref id="bibr48-0961203312465782"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Simone</surname><given-names>N</given-names></name><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>D’Asta</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Pathogenic role of anti-β2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin</article-title>. <source>Hum Reprod Update</source> <year>2007</year>; <volume>13</volume>: <fpage>189</fpage>–<lpage>196</lpage>.</citation></ref>
<ref id="bibr49-0961203312465782"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Simone</surname><given-names>N</given-names></name><name><surname>Di Nicuolo</surname><given-names>F</given-names></name><name><surname>D’Ippolito</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Antiphospholipid antibodies affect human endometrial angiogenesis</article-title>. <source>Biol Reprod</source> <year>2010</year>; <volume>83</volume>: <fpage>212</fpage>–<lpage>219</lpage>.</citation></ref>
<ref id="bibr50-0961203312465782"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D’Ippolito</surname><given-names>S</given-names></name><name><surname>Marana</surname><given-names>R</given-names></name><name><surname>Di Nicuolo</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Effect of low molecular weight heparins on antiphospholipid antibodies-mediated inhibition of endometrial angiogenesis</article-title>. <source>PLoS ONE</source> <year>2012</year>; <volume>7</volume>: <fpage>e29660</fpage>–<lpage>e29660</lpage>.</citation></ref>
<ref id="bibr51-0961203312465782"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derksen</surname><given-names>RH</given-names></name><name><surname>de Groot</surname><given-names>PG</given-names></name></person-group>. <article-title>Towards evidence-based treatment of thrombotic antiphospholipid syndrome</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>470</fpage>–<lpage>474</lpage>.</citation></ref>
<ref id="bibr52-0961203312465782"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name><name><surname>Cuadrado</surname><given-names>M</given-names></name><name><surname>Ruiz-Arruza</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report to a Task Force at the 13th International Congress on Antiphospholipid Antibodies</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>206</fpage>–<lpage>218</lpage>.</citation></ref>
<ref id="bibr53-0961203312465782"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>SM</given-names></name><name><surname>Greer</surname><given-names>IA</given-names></name><name><surname>Pabinger</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Venous thromboembolism, thrombophilias, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [8th edn]</article-title>. <source>Chest</source> <year>2008</year>; <volume>133 (6 Suppl)</volume>: <fpage>844S</fpage>–<lpage>886S</lpage>.</citation></ref>
<ref id="bibr54-0961203312465782"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>SM</given-names></name></person-group>. <article-title>Consultative hematology: the pregnant patient pregnancy loss</article-title>. <source>Haematology Am Soc Hematol Educ Program</source> <year>2010</year>; <volume>2010</volume>: <fpage>166</fpage>–<lpage>172</lpage>.</citation></ref>
<ref id="bibr55-0961203312465782"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Espinosa</surname><given-names>RG</given-names></name><name><surname>Pierangeli</surname><given-names>SS</given-names></name><name><surname>Gharavi</surname><given-names>AE</given-names></name><etal/></person-group>. <article-title>Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholid antibodies</article-title>. <source>Thromb Haemost</source> <year>2002</year>; <volume>87</volume>: <fpage>518</fpage>–<lpage>522</lpage>.</citation></ref>
<ref id="bibr56-0961203312465782"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>MH</given-names></name><name><surname>Pierangeli</surname><given-names>SS</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice</article-title>. <source>Circulation</source> <year>1997</year>; <volume>96</volume>: <fpage>4380</fpage>–<lpage>4384</lpage>.</citation></ref>
<ref id="bibr57-0961203312465782"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hills</surname><given-names>FA</given-names></name><name><surname>Abrahams</surname><given-names>VM</given-names></name><name><surname>Gonzalez-Timón</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Heparin prevents programmed cell death in human trophosblast</article-title>. <source>Mol Hum Reprod</source> <year>2006</year>; <volume>12</volume>: <fpage>237</fpage>–<lpage>243</lpage>.</citation></ref>
<ref id="bibr58-0961203312465782"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oberkersch</surname><given-names>R</given-names></name><name><surname>Attoresi</surname><given-names>A</given-names></name><name><surname>Calabrese</surname><given-names>GC</given-names></name></person-group>. <article-title>Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy</article-title>. <source>Thromb Res</source> <year>2010</year>; <volume>125</volume>: <fpage>e240</fpage>–<lpage>245</lpage>.</citation></ref>
<ref id="bibr59-0961203312465782"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>W</given-names></name></person-group>. <article-title>Complement and the antiphospholipid syndrome</article-title>. <source>Curr Opinion Hematol</source> <year>2011</year>; <volume>18</volume>: <fpage>361</fpage>–<lpage>365</lpage>.</citation></ref>
<ref id="bibr60-0961203312465782"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girardi</surname><given-names>G</given-names></name><name><surname>Redecha</surname><given-names>P</given-names></name><name><surname>Salmon</surname><given-names>JE</given-names></name></person-group>. <article-title>Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation</article-title>. <source>Nat Med</source> <year>2004</year>; <volume>10</volume>: <fpage>1226</fpage>–<lpage>1226</lpage>.</citation></ref>
<ref id="bibr61-0961203312465782"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>JA</given-names></name><name><surname>Cho</surname><given-names>JS</given-names></name></person-group>. <article-title>Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis</article-title>. <source>Ann Vasc Surg</source> <year>2007</year>; <volume>21</volume>: <fpage>50</fpage>–<lpage>55</lpage>.</citation></ref>
<ref id="bibr62-0961203312465782"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girardi</surname><given-names>G</given-names></name><name><surname>Redecha</surname><given-names>P</given-names></name><name><surname>Salmon</surname><given-names>JE</given-names></name></person-group>. <article-title>Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation</article-title>. <source>Nat Med</source> <year>2004</year>; <volume>10</volume>: <fpage>1222</fpage>–<lpage>1226</lpage>.</citation></ref>
<ref id="bibr63-0961203312465782"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samama</surname><given-names>MM</given-names></name><name><surname>Gerotziafas</surname><given-names>GT</given-names></name></person-group>. <article-title>Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide [fondaparinux]</article-title>. <source>Thromb Res</source> <year>2003</year>; <volume>109</volume>: <fpage>1</fpage>–<lpage>11</lpage>.</citation></ref>
<ref id="bibr64-0961203312465782"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banzato</surname><given-names>A</given-names></name><name><surname>Frasson</surname><given-names>R</given-names></name><name><surname>Acqusaliente</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Circulating B2glycoprotein I-IgG anti-B2glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome</article-title>. <source>Lupus</source> <year>2012</year>; <volume>21</volume>: <fpage>784</fpage>–<lpage>786</lpage>.</citation></ref>
<ref id="bibr65-0961203312465782"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amara</surname><given-names>U</given-names></name><name><surname>Fliert</surname><given-names>MA</given-names></name><name><surname>Rittirsch</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Molecular intercommunications between the complement and coagulation systems</article-title>. <source>J Immunol</source> <year>2010</year>; <volume>185</volume>: <fpage>5268</fpage>–<lpage>5236</lpage>.</citation></ref>
<ref id="bibr66-0961203312465782"><label>66</label><citation citation-type="other"><comment>Da Pozzo E, Barsoti MC, Benditelli S, et al. Differential effects of fondaparinux and bemiparin on angiogenic and vasculogenesis-like processes. <italic>Thromb Res</italic> 2012; 130: e113–122</comment>.</citation></ref>
<ref id="bibr67-0961203312465782"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben-Hadj-Khalifa</surname><given-names>S</given-names></name><name><surname>Hézard</surname><given-names>N</given-names></name><name><surname>Almawi</surname><given-names>WY</given-names></name><etal/></person-group>. <article-title>IL-10 modulates fondaparinux inhibition of monocyte-induced thrombin generation</article-title>. <source>J Throm Thrombolysis</source> <year>2011</year>; <volume>32</volume>: <fpage>311</fpage>–<lpage>317</lpage>.</citation></ref>
<ref id="bibr68-0961203312465782"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name></person-group>. <article-title>Lupus and pregnancy: integrating clues from the bench and bedside</article-title>. <source>Eur J Clin Invest</source> <year>2011</year>; <volume>41</volume>: <fpage>672</fpage>–<lpage>678</lpage>.</citation></ref>
<ref id="bibr69-0961203312465782"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wozniacka</surname><given-names>A</given-names></name><name><surname>Lesiak</surname><given-names>A</given-names></name><name><surname>Narbutt</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Chloroquine treatment influences proinflammatory cytokine level in systemic lupus erythematosus patients</article-title>. <source>Lupus</source> <year>2006</year>; <volume>15</volume>: <fpage>268</fpage>–<lpage>275</lpage>.</citation></ref>
<ref id="bibr70-0961203312465782"><label>70</label><citation citation-type="journal"><comment>James DG and Williams WJ. Sarcoidosis and other granulomatous disorders. In: Smith LLH (ed.) <italic>Major problems in internal medicine</italic>, Philadelphia: W.B. Saunders Co, 1985; 24: 1–254</comment>.</citation></ref>
<ref id="bibr71-0961203312465782"><label>71</label><citation citation-type="journal"><comment>Rynes RI. Antimalarial drugs. In: Kelley WN, Harris ED, Ruddyn S and Sledge CB (eds), <italic>Textbook of rheumatology</italic>, 4th ed. Philadelphia: W.B. Saunders, 1993, pp. 731--742</comment>.</citation></ref>
<ref id="bibr72-0961203312465782"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rand</surname><given-names>JH</given-names></name><name><surname>Wu</surname><given-names>XX</given-names></name><name><surname>Lapinski</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome</article-title>. <source>Blood</source> <year>2004</year>; <volume>104</volume>: <fpage>2783</fpage>–<lpage>2790</lpage>.</citation></ref>
<ref id="bibr73-0961203312465782"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>BJ</given-names></name><name><surname>Wu</surname><given-names>XX</given-names></name><name><surname>de Laat</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome</article-title>. <source>Am J Obstet Gynecol</source> <year>2011</year>; <volume>205</volume>: <fpage>485.e17</fpage>–<lpage>23.6</lpage>.</citation></ref>
<ref id="bibr74-0961203312465782"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rand</surname><given-names>JH</given-names></name><name><surname>Wu</surname><given-names>XX</given-names></name><name><surname>Quinn</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug</article-title>. <source>Blood</source> <year>2010</year>; <volume>115</volume>: <fpage>2292</fpage>–<lpage>229</lpage>.</citation></ref>
<ref id="bibr75-0961203312465782"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rand</surname><given-names>JH</given-names></name><name><surname>Wu</surname><given-names>XX</given-names></name><name><surname>Quinn As</surname></name><etal/></person-group>. <article-title>Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay</article-title>. <source>Am J Pathol</source> <year>2003</year>; <volume>163</volume>: <fpage>1193</fpage>–<lpage>1200</lpage>.</citation></ref>
<ref id="bibr76-0961203312465782"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rand</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Quinn</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>460</fpage>–<lpage>469</lpage>.</citation></ref>
<ref id="bibr77-0961203312465782"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>ESPRIT Study</surname><given-names>Group</given-names></name><name><surname>Halkes</surname><given-names>PH</given-names></name><name><surname>van Gijn</surname><given-names>J</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><etal/></person-group>. <article-title>Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin [ESPRIT]: randomised controlled trial</article-title>. <source>Lancet</source> <year>2006</year>; <volume>367</volume>: <fpage>1665</fpage>–<lpage>1673</lpage>.</citation></ref>
<ref id="bibr78-0961203312465782"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>SR</given-names></name><name><surname>Brey</surname><given-names>RL</given-names></name><name><surname>Joseph</surname><given-names>CL</given-names></name><etal/></person-group>. <article-title>Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group</article-title>. <source>Stroke</source> <year>1992</year>; <volume>23</volume>(<issue>2 Suppl</issue>): <fpage>129</fpage>–<lpage>132</lpage>.</citation></ref>
<ref id="bibr79-0961203312465782"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>EM</given-names></name><name><surname>Cockrell</surname><given-names>K</given-names></name><name><surname>Adair</surname><given-names>TH</given-names></name><etal/></person-group>. <article-title>Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic condition in rat placental villous explants</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source> <year>2010</year>; <volume>299</volume>: <fpage>R1629</fpage>–<lpage>1633</lpage>.</citation></ref>
<ref id="bibr80-0961203312465782"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duley</surname><given-names>L</given-names></name><name><surname>Henderson-Smart</surname><given-names>DJ</given-names></name><name><surname>Meher</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Antiplatelet agents for preventing pre-eclampsia and its complications</article-title>. <source>Cochrane database Syst Rev</source> <year>2007</year>; <volume>18</volume>: <fpage>CD004659</fpage>–<lpage>CD004659</lpage>.</citation></ref>
<ref id="bibr81-0961203312465782"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vivaldi</surname><given-names>P</given-names></name><name><surname>Andreotti</surname><given-names>C</given-names></name><name><surname>Mazzoni</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>A primitive catastrophic antiphospholipid syndrome</article-title>. <source>Haematologica</source> <year>1994</year>; <volume>79</volume>: <fpage>173</fpage>–<lpage>176</lpage>.</citation></ref>
<ref id="bibr82-0961203312465782"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burcoglu-O’Ral</surname><given-names>A</given-names></name><name><surname>Erkan</surname><given-names>D</given-names></name><name><surname>Asherson</surname><given-names>R</given-names></name></person-group>. <article-title>Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator</article-title>. <source>J Rheumatol</source> <year>2002</year>; <volume>29</volume>: <fpage>2006</fpage>–<lpage>2011</lpage>.</citation></ref>
<ref id="bibr83-0961203312465782"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lubbe</surname><given-names>W</given-names></name><name><surname>Butler</surname><given-names>W</given-names></name><name><surname>Palmer</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Fetal survival after prednisone suppression of maternal lupus anticoagulant</article-title>. <source>Lancet</source> <year>1983</year>: <volume>1</volume>: <fpage>1361</fpage>–<lpage>1363</lpage>.</citation></ref>
<ref id="bibr84-0961203312465782"><label>84</label><citation citation-type="other"><comment>Axelrod L. Glucocortiocoids. In: Kelley NK, Harris ED, Ruddy S, Sledge C (eds) <italic>Textbook of rheumatology.</italic> 4th ed. Philadelphia, W.B. Saunders Co, 1993, vol 1, pp.779–796</comment>.</citation></ref>
<ref id="bibr85-0961203312465782"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sneiderman</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name></person-group>. <article-title>Effects of corticosteroids on complement and the neutrophil polymorphonuclear leukocyte</article-title>. <source>Transplant Proc</source> <year>1975</year>; <volume>1</volume>: <fpage>1361</fpage>–<lpage>1363</lpage>.</citation></ref>
<ref id="bibr86-0961203312465782"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quenby</surname><given-names>S</given-names></name><name><surname>Farquharson</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Successful pregnancy outcome following 19 consecutive miscarriages</article-title>. <source>Hum Reprod</source> <year>2003</year>; <volume>18</volume>: <fpage>2562</fpage>–<lpage>2564</lpage>.</citation></ref>
<ref id="bibr87-0961203312465782"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bramham</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Nelson-Piercy</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss</article-title>. <source>Blood</source> <year>2011</year>; <volume>117</volume>: <fpage>6948</fpage>–<lpage>6951</lpage>.</citation></ref>
<ref id="bibr88-0961203312465782"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laskin</surname><given-names>CA</given-names></name><name><surname>Bombardieri</surname><given-names>C</given-names></name><name><surname>Hannah</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss</article-title>. <source>N Engl J Med</source> <year>1997</year>; <volume>337</volume>: <fpage>148</fpage>–<lpage>153</lpage>.</citation></ref>
<ref id="bibr89-0961203312465782"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benediktsson</surname><given-names>R</given-names></name><name><surname>Calder</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure</article-title>. <source>Clin Endocrinol [Oxf]</source> <year>1997</year>; <volume>46</volume>: <fpage>161</fpage>–<lpage>166</lpage>.</citation></ref>
<ref id="bibr90-0961203312465782"><label>90</label><citation citation-type="other"><comment>Akther A, Faridi RM, Das V, et al. In vitro up-regulation of HLA-G using dexamethasone and hydrocortisone in first-trimester trophoblast cells of women experiencing recurrent miscarriage. <italic>Tissue Antigens</italic> 2012; 80: 126–135</comment>.</citation></ref>
<ref id="bibr91-0961203312465782"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bayry</surname><given-names>J</given-names></name><name><surname>Negi</surname><given-names>VS</given-names></name></person-group>. <article-title>Intravenous immunoglobulin therapy in rheumatic diseases</article-title>. <source>Nat Rev Rheumatol</source> <year>2011</year>; <volume>7</volume>: <fpage>349</fpage>–<lpage>359</lpage>.</citation></ref>
<ref id="bibr92-0961203312465782"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>TF</given-names></name><name><surname>LaCoursiere</surname><given-names>Y</given-names></name><name><surname>Scott</surname><given-names>JR</given-names></name></person-group>. <article-title>Immunotherapy for recurrent miscarriage</article-title>. <source>Cochrane Database Syst Rev</source> <year>2006</year>; <volume>2</volume>: <fpage>CD000112</fpage>–<lpage>CD000112</lpage>.</citation></ref>
<ref id="bibr93-0961203312465782"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perricone</surname><given-names>R</given-names></name><name><surname>De Carolis</surname><given-names>C</given-names></name><name><surname>Kröegler</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion</article-title>. <source>Rheumatology</source> <year>2008</year>; <volume>47</volume>: <fpage>646</fpage>–<lpage>651</lpage>.</citation></ref>
<ref id="bibr94-0961203312465782"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cervera</surname><given-names>R</given-names></name></person-group>. <article-title>Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome</article-title>. <source>Curr Rheumatol Rep</source> <year>2010</year>; <volume>12</volume>: <fpage>70</fpage>–<lpage>76</lpage>.</citation></ref>
<ref id="bibr95-0961203312465782"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuthill</surname><given-names>J</given-names></name><name><surname>Khamashta</surname><given-names>M</given-names></name></person-group>. <article-title>Management of antiphospholipid syndrome</article-title>. <source>J Autoimmun</source> <year>2009</year>; <volume>33</volume>: <fpage>92</fpage>–<lpage>98</lpage>.</citation></ref>
<ref id="bibr96-0961203312465782"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Triolo</surname><given-names>G</given-names></name><name><surname>Ferrante</surname><given-names>A</given-names></name><name><surname>Ciccia</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulins in the treatment of recurrent fetal loss associated with antiphospholipid antibodies</article-title>. <source>Arthritis Rheum</source> <year>2003</year>; <volume>48</volume>: <fpage>728</fpage>–<lpage>731</lpage>.</citation></ref>
<ref id="bibr97-0961203312465782"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Branch</surname><given-names>D</given-names></name><name><surname>Peaceman</surname><given-names>A</given-names></name><name><surname>Druzin</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A multicenter placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group</article-title>. <source>Am J Obstet Gynecol</source> <year>2000</year>; <volume>182</volume>: <fpage>122</fpage>–<lpage>127</lpage>.</citation></ref>
<ref id="bibr98-0961203312465782"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dendrinos</surname><given-names>S</given-names></name><name><surname>Sakkas</surname><given-names>E</given-names></name><name><surname>Makrakis</surname><given-names>E</given-names></name></person-group>. <article-title>Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome</article-title>. <source>Int J Gynaecol Obstet</source> <year>2009</year>; <volume>104</volume>: <fpage>223</fpage>–<lpage>225</lpage>.</citation></ref>
<ref id="bibr99-0961203312465782"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopera-Vallejo</surname><given-names>AF</given-names></name><name><surname>Alijotas-Reig</surname><given-names>J</given-names></name></person-group>. <article-title>Antiphospholipid antibodies and recurrent implantation failure in in-vitro fertilization. The debate goes on</article-title>. <source>Med Clin [Barc]</source> <year>2011</year>; <volume>137</volume>: <fpage>697</fpage>–<lpage>701</lpage>.</citation></ref>
<ref id="bibr100-0961203312465782"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szodoray</surname><given-names>P</given-names></name><name><surname>Bacskó</surname><given-names>G</given-names></name><name><surname>Lakos</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Combined therapy in pregnancy with primary antiphospholipid syndrome</article-title>. <source>Orv Hetil</source> <year>2003</year>; <volume>144</volume>: <fpage>2411</fpage>–<lpage>2413</lpage>. <comment>[Article in Hungarian]</comment>.</citation></ref>
<ref id="bibr101-0961203312465782"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaquero</surname><given-names>E</given-names></name><name><surname>Lazzarin</surname><given-names>N</given-names></name><name><surname>Valensise</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisolone plus low-dose aspirin</article-title>. <source>Am J Reprod Immunol</source> <year>2001</year>; <volume>45</volume>: <fpage>174</fpage>–<lpage>179</lpage>.</citation></ref>
<ref id="bibr102-0961203312465782"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carp</surname><given-names>HJA</given-names></name></person-group>. <article-title>Intravenous immunoglobulin: effect on infertility and recurrent pregnancy loss</article-title>. <source>Israel Medical Association Journal (IMAJ)</source> <year>2007</year>; <volume>9</volume>: <fpage>877</fpage>–<lpage>880</lpage>.</citation></ref>
<ref id="bibr103-0961203312465782"><label>103</label><citation citation-type="other"><comment>Moraru M, Carbone J, Alecsandru D, et al. Intravenous immunoglobulin treatment increased live birth rate in a Spanish of women with recurrent reproductive failure and expanded CD56[+] cells. <italic>Am J Reprod Immunol</italic> 2012; 68: 75–84</comment>.</citation></ref>
<ref id="bibr104-0961203312465782"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ensom</surname><given-names>MH</given-names></name><name><surname>Stephenson</surname><given-names>MD</given-names></name></person-group>. <article-title>A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories</article-title>. <source>Hum Reprod</source> <year>2011</year>; <volume>26</volume>: <fpage>2283</fpage>–<lpage>228</lpage>.</citation></ref>
<ref id="bibr105-0961203312465782"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nurmohamed</surname><given-names>MT</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name></person-group>. <article-title>Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis</article-title>. <source>Drugs</source> <year>2005</year>; <volume>65</volume>: <fpage>661</fpage>–<lpage>694</lpage>.</citation></ref>
<ref id="bibr106-0961203312465782"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Brito-Zeron</surname><given-names>P</given-names></name><name><surname>Muñoz</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Autoimmune diseases induced by TNF-targeted therapies</article-title>. <source>Medicine (Baltimore)</source> <year>2007</year>; <volume>86</volume>: <fpage>242</fpage>–<lpage>251</lpage>.</citation></ref>
<ref id="bibr107-0961203312465782"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bongartz</surname><given-names>T</given-names></name><name><surname>Sutton</surname><given-names>AJ</given-names></name><name><surname>Sweeting</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials</article-title>. <source>Journal of American Medical Association (JAMA)</source> <year>2006</year>; <volume>295</volume>: <fpage>2275</fpage>–<lpage>2285</lpage>.</citation></ref>
<ref id="bibr108-0961203312465782"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berthelot</surname><given-names>JM</given-names></name><name><surname>De Bandt</surname><given-names>M</given-names></name><name><surname>Goupille</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature</article-title>. <source>Joint Bone Spine</source> <year>2009</year>; <volume>76</volume>: <fpage>28</fpage>–<lpage>34</lpage>.</citation></ref>
<ref id="bibr109-0961203312465782"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salmon</surname><given-names>JE</given-names></name><name><surname>Alpert</surname><given-names>D</given-names></name></person-group>. <article-title>Are we coming to terms with tumor necrosis factor inhibition in pregnancy?</article-title> <source>Arthritis Rheum</source> <year>2006</year>; <volume>54</volume>: <fpage>2353</fpage>–<lpage>235</lpage>.</citation></ref>
<ref id="bibr110-0961203312465782"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosner</surname><given-names>I</given-names></name><name><surname>Haddad</surname><given-names>A</given-names></name><name><surname>Boulman</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Pregnancy in rheumatology patients exposed to anti-tumor [TNF]-alpha therapy</article-title>. <source>Rheumatology</source> <year>2007</year>; <volume>46</volume>: <fpage>1508</fpage>–<lpage>1509</lpage>.</citation></ref>
<ref id="bibr111-0961203312465782"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bank</surname><given-names>LHB</given-names></name></person-group>. <article-title>Unexpected dramatic clinical response of psoriasis lesions and unexpected pregnancy in an infertile patient in response to treatment with anti-tumor necrosis factor monoclonal antibody for Crohn’s disease</article-title>. <source>Am J Gastroenterol</source> <year>2002</year>; <volume>97</volume>(<issue>Abstract</issue>): <fpage>S260</fpage>–<lpage>S260</lpage>.</citation></ref>
<ref id="bibr112-0961203312465782"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Roberto-Perez-Alvarez</surname></name><name><surname>Diaz-Lagares</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Autoimmune diseases induced by biological agents: a double-edged sword?</article-title> <source>Autoimmun Rev</source> <year>2010</year>; <volume>9</volume>: <fpage>188</fpage>–<lpage>193</lpage>.</citation></ref>
<ref id="bibr113-0961203312465782"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winger</surname><given-names>EE</given-names></name><name><surname>Reed</surname><given-names>JL</given-names></name><name><surname>Ashoush</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Treatment with Adalimumab [Humira<sup>R</sup>] and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF</article-title>. <source>Am J Reprod Immunol</source> <year>2009</year>; <volume>61</volume>: <fpage>113</fpage>–<lpage>120</lpage>.</citation></ref>
<ref id="bibr114-0961203312465782"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winger</surname><given-names>EE</given-names></name><name><surname>Reed</surname><given-names>JL</given-names></name></person-group>. <article-title>Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion</article-title>. <source>Am J Reprod Immunol</source> <year>2008</year>; <volume>60</volume>: <fpage>8</fpage>–<lpage>16</lpage>.</citation></ref>
<ref id="bibr115-0961203312465782"><label>115</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beer</surname><given-names>AE</given-names></name></person-group>. <article-title>Th-1/Th-2 natural killer cell activation systemically and locally in the endometrium and therapeutic options</article-title>. <source>Am J Reprod Immunol</source> <year>2001</year>; <volume>45</volume>: <fpage>23</fpage>–<lpage>23</lpage>.</citation></ref>
<ref id="bibr116-0961203312465782"><label>116</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mangubat</surname><given-names>CP</given-names></name><name><surname>Thaker</surname><given-names>PP</given-names></name><name><surname>Cavalcante</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Etanercept and immune treatment in multiple IVF failures</article-title>. <source>Am J Reprod Immunol</source> <year>2001</year>; <volume>45</volume>: <fpage>24</fpage>–<lpage>24</lpage>.</citation></ref>
<ref id="bibr117-0961203312465782"><label>117</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaouat</surname><given-names>G</given-names></name><name><surname>Assal-Meliani</surname><given-names>A</given-names></name><name><surname>Martal</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>IL-10 prevents naturally occurring fetal loss in the CBAxDBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau</article-title>. <source>J Immunol</source> <year>1995</year>; <volume>154</volume>: <fpage>426</fpage>–<lpage>428</lpage>.</citation></ref>
<ref id="bibr118-0961203312465782"><label>118</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>XH</given-names></name><name><surname>Shi</surname><given-names>WY</given-names></name><name><surname>Ma</surname><given-names>AT</given-names></name><etal/></person-group>. <article-title>Effects of Radix scutellariae and Rhizoma atractylodis on LPS-induced abortion and the uterine IL-10 contents in mice</article-title>. <source>Am J Chin Med</source> <year>2008</year>; <volume>36</volume>: <fpage>141</fpage>–<lpage>148</lpage>.</citation></ref>
<ref id="bibr119-0961203312465782"><label>119</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>SM</given-names></name><name><surname>Shah</surname><given-names>MKH</given-names></name><name><surname>Williams</surname><given-names>SG</given-names></name><etal/></person-group>. <article-title>Immunological mechanisms of pentoxifylline in chronic heart failure</article-title>. <source>Eur J Cardiol</source> <year>2009</year>; <volume>XX</volume>: <fpage>113</fpage>–<lpage>118</lpage>.</citation></ref>
<ref id="bibr120-0961203312465782"><label>120</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Pentoxifylline for endometriosis</article-title>. <source>Cochrane Database Syst Rev</source> <year>2012</year>; <volume>1</volume>: <fpage>CD007677</fpage>–<lpage>CD007677</lpage>.</citation></ref>
<ref id="bibr121-0961203312465782"><label>121</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Creus</surname><given-names>M</given-names></name><name><surname>Fabregues</surname><given-names>F</given-names></name><name><surname>Carmona</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial</article-title>. <source>Hum Reprod</source> <year>2008</year>; <volume>23</volume>: <fpage>1910</fpage>–<lpage>1916</lpage>.</citation></ref>
<ref id="bibr122-0961203312465782"><label>122</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bick</surname><given-names>RL</given-names></name></person-group>. <article-title>Antiphospholipid thrombosis syndromes</article-title>. <source>Clin Appl Thromb Hemost</source> <year>2001</year>; <volume>7</volume>: <fpage>241</fpage>–<lpage>258</lpage>.</citation></ref>
<ref id="bibr123-0961203312465782"><label>123</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Letur-Konirsch</surname><given-names>H</given-names></name><name><surname>Delanian</surname><given-names>S</given-names></name></person-group>. <article-title>Successful pregnancies after combined pentoxifylline-tocopherol treatment in women with premature ovarian failure who are resistant to hormone replacement therapy</article-title>. <source>Fertil Steril</source> <year>2003</year>; <volume>79</volume>: <fpage>439</fpage>–<lpage>441</lpage>.</citation></ref>
<ref id="bibr124-0961203312465782"><label>124</label><citation citation-type="other"><comment>Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. <italic>Blood</italic> 2012; 119: 5859–5870</comment>.</citation></ref>
<ref id="bibr125-0961203312465782"><label>125</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnson</surname><given-names>Y</given-names></name><name><surname>Amital</surname><given-names>H</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Vitamin D and autoimmunity: new aetiological and therapeutic considerations</article-title>. <source>Ann Rheum Dis</source> <year>2007</year>; <volume>66</volume>: <fpage>1137</fpage>–<lpage>1142</lpage>.</citation></ref>
<ref id="bibr126-0961203312465782"><label>126</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agmon-Levin</surname><given-names>N</given-names></name><name><surname>Blank</surname><given-names>M</given-names></name><name><surname>Zandman-Goddard</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression</article-title>. <source>Ann Rheum Dis</source> <year>2011</year>; <volume>70</volume>: <fpage>145</fpage>–<lpage>150</lpage>.</citation></ref>
<ref id="bibr127-0961203312465782"><label>127</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>G</given-names></name></person-group>. <article-title>Hughes syndrome: the antiphospholipid syndrome -a clinical overview</article-title>. <source>Clin Rev Allergy Immunol</source> <year>2007</year>; <volume>32</volume>: <fpage>3</fpage>–<lpage>12</lpage>.</citation></ref>
<ref id="bibr128-0961203312465782"><label>128</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pierangeli</surname><given-names>SS</given-names></name><name><surname>Vega-Ostertag</surname><given-names>ME</given-names></name><name><surname>Gonzalez</surname><given-names>EB</given-names></name></person-group>. <article-title>New targeted therapies for treatment of thrombosis in antiphospholipid syndrome</article-title>. <source>Expert Rev Mol Med</source> <year>2007</year>; <volume>9</volume>: <fpage>1</fpage>–<lpage>15</lpage>.</citation></ref>
<ref id="bibr129-0961203312465782"><label>129</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raschi</surname><given-names>E</given-names></name><name><surname>Borghi</surname><given-names>MO</given-names></name><name><surname>Grossi</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Toll-like receptors: another player in the pathogenesis of the antiphospholipid syndrome</article-title>. <source>Lupus</source> <year>2008</year>; <volume>87</volume>: <fpage>214</fpage>–<lpage>220</lpage>.</citation></ref>
<ref id="bibr130-0961203312465782"><label>130</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sadeghi</surname><given-names>K</given-names></name><name><surname>Wessner</surname><given-names>B</given-names></name><name><surname>Laggner</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns</article-title>. <source>Eur J Immunol</source> <year>2006</year>; <volume>36</volume>: <fpage>361</fpage>–<lpage>370</lpage>.</citation></ref>
<ref id="bibr131-0961203312465782"><label>131</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broussas</surname><given-names>M</given-names></name><name><surname>Cornillet- Levefre</surname><given-names>P</given-names></name><name><surname>Potron</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of the A3 adenosine receptor</article-title>. <source>Thromb Haemost</source> <year>2002</year>; <volume>88</volume>: <fpage>123</fpage>–<lpage>130</lpage>.</citation></ref>
<ref id="bibr132-0961203312465782"><label>132</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burcuglu-O’Ral</surname><given-names>A</given-names></name><name><surname>Erkan</surname><given-names>D</given-names></name><name><surname>Asherson</surname><given-names>R</given-names></name></person-group>. <article-title>Treatment of catastrophic antiphospholipid syndrome with defibrotide: a proposed vascular endothelial cell modulator</article-title>. <source>J Rheumatol</source> <year>2002</year>; <volume>29</volume>: <fpage>2006</fpage>–<lpage>2011</lpage>.</citation></ref>
<ref id="bibr133-0961203312465782"><label>133</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Napoleone</surname><given-names>E</given-names></name><name><surname>Di Santo</surname><given-names>A</given-names></name><name><surname>Camera</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes</article-title>. <source>Circ Res</source> <year>2002</year>; <volume>86</volume>: <fpage>139</fpage>–<lpage>143</lpage>.</citation></ref>
<ref id="bibr134-0961203312465782"><label>134</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>J, Mahmud</surname><given-names>SA</given-names></name><name><surname>Bitterman</surname><given-names>PB</given-names></name><etal/></person-group>. <article-title>Histone deacetylase inhibitors suppress TF-KappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes</article-title>. <source>J Biol Chem</source> <year>2007</year>; <volume>282</volume>: <fpage>24 408</fpage>–<lpage>24418</lpage>.</citation></ref>
<ref id="bibr135-0961203312465782"><label>135</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinev</surname><given-names>AV</given-names></name><name><surname>Roubey</surname><given-names>RAS</given-names></name></person-group>. <article-title>Tissue factor in the antiphospholipid syndrome</article-title>. <source>Lupus</source> <year>2008</year>; <volume>17</volume>: <fpage>952</fpage>–<lpage>958</lpage>.</citation></ref>
<ref id="bibr136-0961203312465782"><label>136</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raschi</surname><given-names>E</given-names></name><name><surname>Borghi</surname><given-names>MO</given-names></name><name><surname>Grossi</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome</article-title>. <source>Lupus</source> <year>2008</year>; <volume>17</volume>: <fpage>937</fpage>–<lpage>942</lpage>.</citation></ref>
<ref id="bibr137-0961203312465782"><label>137</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lockhin</surname><given-names>MD</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Laskin</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies</article-title>. <source>Arthritis Rheum</source> <year>2012</year>; <volume>64</volume>: <fpage>2311</fpage>–<lpage>2318</lpage>.</citation></ref>
</ref-list>
</back>
</article>